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Abstract	  
	  Pancreatic	  cancer	  is	  one	  of	  the	  leading	  causes	  of	  cancer	  deaths	  in	  the	  nation,	  as	  only	  1-­‐6%	  of	  patients	  survive	  five	  years	  past	  their	  diagnosis.	  With	  such	  bleak	  prospects	  for	  survival,	  doctors	  and	  scientists	  have	  been	  struggling	  with	  developing	  therapeutics	  that	  could	  more	  effectively	  target	  and	  treat	  pancreatic	  cancer.	  Nanomedicine,	  an	  increasingly	  popular	  field	  of	  research,	  offers	  a	  way	  to	  subvert	  many	  problems	  with	  current	  pancreatic	  cancer	  treatments.	  Nanovehicles	  are	  functionally	  flexible	  platforms	  for	  the	  selective	  delivery	  of	  therapeutics	  such	  as	  boron-­‐neutron	  capture	  therapy.	  Boron-­‐neutron	  capture	  therapy	  (BNCT)	  is	  a	  radiation-­‐based	  therapy	  in	  which	  boron-­‐10	  isotopes	  are	  provoked	  into	  alpha	  decay	  through	  the	  capture	  of	  thermal	  neutrons.	  	  We	  hope	  to	  selectively	  administer	  BNCT	  to	  pancreatic	  cancer	  cells	  by	  co-­‐conjugating	  boron-­‐10	  rich	  polymers	  and	  pancreatic	  cancer-­‐specific	  antibodies	  to	  gold	  nanoparticles.	  The	  proposed	  goal	  of	  this	  thesis	  is	  to	  produce	  a	  stable	  gold	  nanovehicle	  capable	  of	  carrying	  both	  targeting	  antibodies	  and	  boron-­‐10	  rich	  polymers.	  Antibodies	  and	  peptides	  are	  modified	  with	  biotin	  moieties	  and	  conjugation	  to	  the	  nanovehicle	  occurs	  through	  avidin-­‐biotin	  interactions,	  which	  have	  one	  of	  the	  lowest	  naturally	  occurring	  dissociation	  constants	  ever	  studied.	  Particles	  were	  studied	  using	  spectroscopic	  and	  light	  scattering	  techniques,	  as	  well	  as	  pull-­‐down	  and	  electrophoretic	  methods.	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Introduction	  	  	   Nanomedicine	  is	  a	  growing	  field	  on	  the	  front	  lines	  of	  the	  fight	  against	  disease.	  Scientists	  and	  medical	  professionals	  have	  increasingly	  been	  turning	  their	  attention	  to	  manipulating	  disease	  pathways	  on	  a	  cellular	  and	  molecular	  level	  as	  a	  way	  of	  stopping	  illnesses	  such	  as	  cancer	  in	  their	  tracks.	  	  Nanomedicine	  spans	  the	  gamut	  from	  finely	  milled	  drug	  particles,	  such	  as	  the	  anti-­‐nausea	  medication	  Emend™,	  on	  the	  market	  since	  2003,	  to	  specially	  designed,	  complex	  metal	  or	  lipid	  nanoparticles.	  Nanoscience	  has	  opened	  the	  doors	  for	  tissue-­‐specific	  treatments,	  and	  it	  has	  been	  shown	  that	  incorporating	  drugs	  as	  part	  of	  nanotherapies	  can	  lead	  to	  a	  hundred-­‐fold	  dosage	  reduction.1	  Gold	  nanoparticles,	  in	  particular,	  have	  shown	  promise	  for	  biomedicine.	  On	  the	  nanoscale,	  gold	  exhibits	  remarkable	  properties	  that	  makes	  it	  attractive	  for	  both	  treatments	  and	  as	  a	  carrier	  for	  therapeutic	  agents,	  such	  as	  biocompatibility,	  size-­‐dependent	  electro-­‐optical	  properties,	  and	  catalytic	  properties.2,3	  	  	   The	  uses	  for	  gold	  in	  nanomedicine	  are	  stunningly	  abundant.	  For	  example,	  the	  electro-­‐optical	  properties	  of	  gold	  make	  it	  increasingly	  popular	  in	  biological	  imaging,	  including	  cancer	  diagnoses.1,3,4	  Gold	  nanoparticles	  have	  size-­‐dependent	  light	  absorption	  and	  scattering	  patterns	  based	  on	  their	  surface	  plasmon	  resonance.5	  When	  particles	  are	  below	  50	  nm	  in	  diameter,	  the	  mean-­‐free	  path	  of	  surface	  electrons	  is	  greater	  than	  the	  size	  of	  the	  particle,	  leading	  to	  electron	  interactions	  at	  the	  surface	  of	  the	  particles.5	  In	  the	  presence	  of	  light,	  the	  spin	  of	  these	  electrons	  is	  polarized	  and	  otherwise	  shifted,	  leading	  to	  light	  absorption	  at	  specific	  wavelengths	  based	  on	  size.5	  Because	  of	  these	  optical	  properties,	  gold	  nanoparticles	  can	  be	  imaged	  in	  dark	  field,	  as	  a	  result	  of	  their	  light	  scattering	  potential,	  or	  as	  a	  contrast	  agent	  in	  bright	  field	  or	  transmission	  electron	  microscopy.6	  In	  addition,	  gold	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nanoparticles	  can	  be	  used	  for	  photothermal	  therapies,	  in	  which	  gold	  nanoparticles	  are	  excited	  with	  light	  and	  produce	  enough	  heat	  to	  kill	  diseased	  cells.1	  Photothermal	  imaging	  and	  therapy	  are	  both	  typically	  used	  for	  cancer	  treatments,	  as	  it	  has	  been	  found	  that	  nanoparticles	  naturally	  concentrate	  in	  cancerous	  tissue	  due	  to	  leaky	  vasculature.7	  	   One	  of	  the	  largest	  fields	  of	  research	  for	  gold	  nanoparticles	  in	  biomedicine	  is	  the	  use	  of	  gold	  nanoparticles	  as	  carriers	  for	  drugs	  and	  other	  therapeutic	  agents.	  Gold	  nanoparticles	  are	  biocompatible	  and	  have	  a	  high	  surface-­‐area-­‐to-­‐volume	  ratio,	  and	  readily	  form	  covalent	  bonds	  with	  thiols	  and	  amines.1,3,4,8	  Each	  of	  these	  properties	  makes	  gold	  nanoparticles	  an	  ideal	  system	  for	  tethering	  drug	  conjugates	  and	  other	  forms	  of	  targeted	  therapeutics.	  For	  example,	  gold	  nanoparticles	  conjugated	  with	  DNA	  binding	  peptides	  have	  been	  used	  in	  gene	  transfection.8	  Targeting	  peptides	  and	  antibodies	  are	  commonly	  used	  to	  direct	  these	  therapies	  to	  their	  desired	  targets.3,8	  Targeting	  using	  antibodies	  will	  be	  discussed	  below.	  Many	  researchers	  are	  also	  focusing	  on	  using	  the	  small	  size	  and	  high	  surface	  area-­‐to-­‐volume	  ratio	  of	  gold	  nanoparticles	  to	  increase	  drug	  concentrations	  in	  diseased	  tissue,	  such	  as	  tumors.1,3,9	  In	  2014,	  Kao	  et	  al.	  demonstrated	  that	  cetuximab	  (Erbitux®)	  and	  anti-­‐epidermal	  growth	  factor	  receptor	  antibodies	  could	  be	  conjugated	  to	  gold	  nanoparticles	  and	  selectively	  target	  and	  treat	  cancerous	  tissue	  in	  vivo	  in	  a	  living	  mouse	  model.9	  After	  treatment	  with	  these	  particles,	  cancerous	  tissue	  not	  only	  demonstrated	  a	  higher	  concentration	  of	  cetuximab	  relative	  to	  systemic	  exposure	  to	  cetuximab,	  but	  also	  healthy	  tissue	  underwent	  less	  damage	  through	  toxic	  side	  effects.9	  	   Cancer	  has	  become	  a	  major	  focus	  of	  nanomedicine,	  as	  it	  offers	  the	  possibility	  of	  reducing	  collateral	  damage	  to	  healthy	  tissue	  caused	  by	  current	  cancer	  therapies.1	  Nanoscience	  is	  especially	  exciting	  in	  the	  context	  of	  traditionally	  challenging	  cancers,	  such	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as	  pancreatic	  adenocarcinoma.	  Pancreatic	  cancer	  is	  the	  fourth	  leading	  cause	  of	  deaths	  related	  to	  cancer	  in	  America.10	  As	  seen	  in	  Figure	  1,	  the	  pancreas	  is	  located	  deep	  within	  the	  abdomen,	  behind	  the	  stomach,	  making	  surgical	  treatment	  difficult.	  In	  addition,	  pancreatic	  cancer	  presents	  with	  non-­‐specific	  symptoms,	  such	  as	  jaundice,	  nausea,	  gastric	  distress,	  and	  back	  pain,	  complicating	  diagnosis.11	  Although	  surgical	  resection	  has	  a	  low	  mortality	  rate	  in	  hospitals	  that	  routinely	  practice	  pancreaticoduodenectomies,	  resection	  is	  still	  difficult	  and	  has	  many	  unpleasant	  side	  effects,	  reducing	  the	  number	  of	  eligible	  patients	  who	  undergo	  surgical	  resection.10	  Those	  who	  undergo	  surgical	  resection	  have	  a	  20–25%	  five-­‐year	  survival	  rate.10	  Unfortunately,	  most	  patients	  are	  not	  eligible	  for	  surgery,	  as	  most	  cases	  of	  pancreatic	  cancer	  are	  caught	  in	  late	  stages,	  when	  the	  cancer	  has	  already	  metastasized.11	  Mid-­‐	  and	  late-­‐stage	  pancreatic	  cancers	  are	  typically	  treated	  with	  gemcitabine,	  a	  fluorinated	  nucleoside	  analogue,	  as	  a	  chemotherapeutic	  agent.10	  In	  late	  stage	  cancers,	  gemcitabine	  can	  extend	  life	  expectancy	  a	  few	  months,	  but	  the	  overall	  five-­‐year	  survival	  rate	  of	  non-­‐resectable	  pancreatic	  cancer	  has	  stagnated	  at	  approximately	  5%	  since	  the	  1990s,	  despite	  significant	  work	  on	  the	  subject.11,12	  	  
	  
Figure	  1:	  Location	  of	  the	  pancreas	  within	  the	  human	  body.	  ©	  Blausen	  Medical	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   With	  these	  sobering	  facts	  at	  hand,	  the	  goal	  of	  this	  project	  is	  to	  use	  the	  biomedical	  advantages	  of	  gold	  nanoparticles	  to	  develop	  a	  nanovehicle	  for	  the	  targeted	  treatment	  of	  pancreatic	  cancer.	  	  Gold	  nanoparticles	  are	  optimal	  for	  this	  role,	  as	  they	  can	  circumvent	  problems	  posed	  by	  the	  location	  of	  the	  pancreas	  by	  traveling	  through	  the	  bloodstream	  directly	  to	  diseased	  tissue.	  In	  addition,	  gold	  nanoparticles	  can	  deliver	  high	  concentrations	  of	  desired	  treatment	  agents	  directly	  to	  cancerous	  tissue,	  reducing	  unpleasant	  side	  effects	  associated	  with	  traditional	  chemotherapeutic	  treatments	  such	  as	  courses	  of	  gemcitabine.	  About	  50%	  of	  pancreatic	  ductal	  adenocarcinoma	  (PDAC),	  as	  well	  as	  95%	  of	  various	  colorectal	  cancers,	  overexpress	  glycoprotein	  A33,	  an	  immunoglobulin,	  on	  the	  outside	  of	  the	  plasma	  membrane.13	  Glycoprotein	  A33	  gives	  us	  a	  target	  for	  directing	  nanoparticle	  binding,	  as	  it	  provides	  a	  distinct	  physical	  marker	  that	  differentiates	  PDAC	  cells	  from	  healthy	  tissue.	  	  My	  aim	  is	  to	  synthesize	  a	  gold-­‐coated	  iron-­‐oxide	  nanoparticle	  enhanced	  with	  a	  polymer	  for	  biocompatibility	  and	  targeting	  and	  treatment	  moieties	  based	  on	  the	  unique	  characteristics	  of	  pancreatic	  cancer.	  	  The	  proposed	  nanovehicle,	  shown	  in	  Figure	  2,	  is	  composed	  of	  carefully	  selected	  moieties	  that	  each	  contribute	  to	  the	  particles’	  stability	  and	  function,	  and	  will	  be	  explained	  in	  detail	  below,	  from	  the	  inside	  to	  the	  outer	  moieties.	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Figure	  2:	  Representation	  of	  proposed	  nanovehicle.	  Image	  by	  Stephanie	  Schmitt	  '13.	  	   At	  the	  center	  of	  the	  proposed	  nanovehicle	  is	  a	  gold-­‐coated	  iron	  oxide	  particle.	  This	  particle	  would	  combine	  the	  advantageous	  properties	  of	  gold	  nanospheres,	  such	  as	  biocompatibility	  and	  optical	  properties,	  discussed	  previously,	  with	  favorable	  magnetic	  resonance	  imaging	  properties	  of	  iron	  oxide.	  At	  the	  time	  of	  this	  writing,	  pure	  gold	  nanoparticles	  are	  used	  as	  a	  model	  system	  for	  the	  testing	  and	  conjugation	  of	  surface	  moieties	  while	  collaborators	  develop	  gold-­‐coated	  iron	  oxide	  particles.	  The	  presence	  of	  iron	  oxide	  would	  make	  these	  particles	  possible	  to	  image	  with	  nuclear	  magnetic	  resonance	  imaging	  (MRI),	  so	  that	  the	  presence	  of	  our	  particles	  in	  the	  pancreas	  could	  be	  ensured	  before	  treatment	  began.	  The	  next	  important	  piece	  of	  the	  proposed	  nanovehicle	  is	  a	  complete	  polyethylene	  glycol	  (PEG)	  coating.	  PEG	  is	  commonly	  used	  for	  increasing	  the	  biocompatibility	  of	  nanoparticles.14	  PEG	  coatings	  are	  used	  to	  reduce	  protein	  adsorption	  and	  non-­‐specific	  cell	  adhesion,	  both	  significant	  problems	  for	  targeted	  therapy.2,14	  PEG	  coated	  particles	  are	  also	  less	  susceptible	  to	  recognition	  and	  clearance	  by	  the	  reticuloendothelial	  system.15	  In	  addition,	  there	  is	  some	  evidence	  that	  PEG	  is	  capable	  of	  excluding	  proteins	  from	  adsorbing	  to	  the	  surface	  of	  nanoparticles,	  enhancing	  the	  stability	  of	  nanoparticles	  within	  the	  body,	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where	  particles	  will	  be	  exposed	  to	  high	  amounts	  of	  protein	  in	  the	  blood	  and	  extracellular	  matrix.14	  The	  Food	  and	  Drug	  Administration	  has	  granted	  approval	  to	  use	  PEG	  for	  a	  wide	  range	  of	  uses,	  including	  biomaterial	  coatings.16	  Several	  nanotechnologies	  currently	  on	  the	  market	  utilize	  PEG	  coats,	  including	  Doxil,	  an	  antitumor	  medication	  on	  the	  market	  since	  June	  1999.16	  For	  the	  purposes	  of	  this	  study,	  two	  types	  of	  heterobifunctional	  PEG,	  shown	  in	  Figure	  3,	  are	  used,	  each	  with	  a	  thiol	  terminus	  to	  form	  covalent	  bonds	  with	  the	  gold	  shell.	  One	  PEG	  features	  a	  carboxylated	  terminus	  (C-­‐PEG)	  (Figure	  3A);	  the	  main	  purpose	  of	  this	  PEG	  is	  to	  space	  out	  the	  neighboring	  biotin-­‐PEG	  moieties	  and	  to	  give	  our	  nanoparticles	  a	  negative	  surface	  charge,	  which	  should	  reduce	  nonspecific	  adsorption	  to	  cells,	  as	  the	  surfaces	  of	  mammalian	  cells	  are	  also	  negatively	  charged17.	  The	  second	  PEG	  is	  terminated	  with	  biotin	  (B-­‐PEG),	  a	  commonly	  used	  biological	  linker	  also	  known	  as	  vitamin	  B7	  (Figure	  3B).	  This	  biotin	  is	  the	  key	  to	  further	  functionalization,	  as	  our	  particle	  takes	  advantage	  of	  avidin-­‐biotin	  interactions.	  
	  
Figure	  3:	  Heterobifunctional	  polyethylene	  glycol	  polymers	  for	  surface	  functionalization.	  Biotin-­‐PEG-­‐thiol,	  used	  for	  further	  conjugation	  (top	  structure)	  while	  carboxy-­‐PEG-­‐thiol,	  a	  molecular	  spacer,	  is	  shown	  second.	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Avidin,	  shown	  in	  Figure	  4,	  the	  next	  molecule	  on	  our	  nanovehicle,	  is	  a	  homotetrameric	  egg	  white	  protein	  found	  in	  many	  biotechnologies.18	  A	  total	  of	  four	  biotin	  molecules	  purportedly	  can	  bind	  avidin,	  one	  at	  each	  subunit,	  with	  a	  dissociation	  constant	  of	  10-­‐15	  M,	  making	  this	  one	  of	  the	  strongest	  biological	  interactions	  in	  existence.18,19	  Because	  bonds	  in	  biotin-­‐avidin	  complexes	  are	  difficult	  to	  disrupt	  once	  they	  form,	  they	  are	  frequently	  used	  as	  probes	  and	  in	  purification	  systems	  and	  immunoassays.19	  	  
	  
Figure	  4:	  The	  biotin-­‐avidin	  complex.	  The	  biotin-­‐avidin	  binding	  complex	  is	  centrally	  important	  to	  our	  nanovehicle.	  Above	  is	  an	  image	  of	  a	  homodimer	  of	  avidin,	  one	  chain	  in	  bright	  green	  and	  one	  chain	  in	  cyan,	  capable	  of	  binding	  two	  biotins,	  shown	  in	  magenta.	  The	  right	  is	  a	  space-­‐filling	  model	  of	  avidin	  with	  biotin	  bound,	  and	  the	  left	  is	  a	  model	  of	  the	  backbone	  of	  avidin	  chains	  with	  secondary	  structure	  isolated,	  to	  show	  that	  biotin	  fits	  deep	  within	  a	  beta-­‐barrel.	  	  	   For	  the	  purposes	  of	  our	  nanovehicle,	  avidin	  will	  serve	  as	  the	  bridge	  between	  our	  stabilizing	  PEG	  coat	  and	  the	  treatment	  and	  targeting	  moieties	  that	  will	  give	  our	  nanovehicle	  its	  unique	  function.	  Avidin	  binds	  nanoparticle	  conjugated	  B-­‐PEG	  at	  one	  subunit,	  leaving	  three	  sites	  open	  for	  further	  functionalization.	  These	  biotin-­‐binding	  sites	  will	  bind	  biotinylated	  antibodies	  against	  pancreatic	  cancer	  cells	  and	  polymers	  rich	  in	  boron-­‐10,	  a	  therapeutic	  agent	  used	  for	  boron	  neutron	  capture	  therapy	  (BNCT).	  Though	  this	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nanovehicle	  will	  be	  used	  to	  treat	  pancreatic	  cancer	  with	  BNCT,	  using	  avidin	  as	  a	  central	  piece	  of	  the	  construct	  means	  that	  other	  antibodies	  and	  treatments	  could	  be	  conjugated	  to	  particles	  in	  a	  similar	  way,	  opening	  up	  the	  possibility	  of	  using	  this	  design	  to	  treat	  multitudes	  of	  cancers,	  beyond	  just	  pancreatic	  adenocarcinoma.	  	  	   The	  key	  to	  the	  selectivity	  of	  this	  nanovehicle	  is	  the	  presence	  of	  a	  gpA33	  targeting	  antibody,	  such	  as	  31.1	  or	  A33.	  Antibodies	  are	  a	  hugely	  important	  piece	  in	  targeted	  therapies	  and	  imaging.20-­‐23	  For	  example,	  antibodies	  are	  commonly	  used	  in	  particle	  tracking	  studies	  in	  protein	  binding	  or	  receptor-­‐mediated	  endocytosis.20,21,23	  Antibodies	  have	  been	  used	  to	  study	  surface	  trafficking	  of	  neurotransmitters.22	  Single	  particle	  tracking	  studies	  have	  even	  been	  performed	  with	  anti-­‐HER2	  antibody	  (e.g.	  trastuzumab)	  conjugated	  quantum	  dots,	  for	  the	  purpose	  of	  understanding	  how	  nanomaterials	  with	  targeting	  antibodies	  interact	  with	  breast	  tumor	  tissue	  in	  mice.23	  Breast	  cancer	  treatment	  trastuzumab	  was	  conjugated	  to	  quantum	  dots,	  which	  were	  internalized	  into	  breast	  cancer	  cells	  grown	  in	  vitro.21	  Researchers	  also	  found	  that	  these	  particles	  induced	  a	  higher	  concentration	  of	  trastuzumab	  in	  cancer	  cells	  compared	  to	  healthy	  tissue.21	  	  Additionally,	  it	  is	  possible	  that	  antibodies	  could	  be	  used	  as	  a	  diagnostic	  tool	  in	  cancer	  screenings	  before	  symptoms	  occur,	  such	  as	  those	  given	  to	  at-­‐risk	  patients.24	  Arlen	  et	  
al.	  notes	  that	  premalignant	  colorectal	  cancer	  cells	  shed	  proteins	  that	  act	  as	  biomarkers;	  monoclonal	  antibodies	  raised	  against	  these	  markers	  can	  then	  be	  used	  on	  excreted	  extracts	  as	  a	  non-­‐invasive	  diagnostic.	  Such	  measures	  are	  particularly	  promising	  to	  researchers,	  since	  one	  of	  the	  reasons	  colorectal	  cancers	  are	  so	  deadly	  is	  late	  detection.24	  Better	  still,	  scientists	  believe	  that	  once	  cancer	  has	  been	  detected,	  the	  same	  monoclonal	  antibodies	  could	  be	  used	  to	  treat	  the	  very	  cancers	  they	  found.24	  If	  these	  antibodies	  were	  injected	  into	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the	  blood	  stream	  and	  bound	  tightly	  to	  cancerous	  tissue,	  they	  would	  trigger	  an	  immune	  response,	  known	  as	  antibody	  dependent	  cell	  cytotoxicity	  (ADCC),	  and	  the	  body	  itself	  would	  destroy	  cancerous	  tissue.	  24	  In	  the	  case	  of	  our	  particle,	  CHO	  31.1	  is	  a	  monoclonal	  antibody	  raised	  against	  a	  biomarker	  for	  pancreatic	  cancer,	  glycoprotein	  A33	  (gpA33).	  It	  has	  been	  found	  that	  up	  to	  95%	  of	  colorectal	  cancers	  overexpress	  glycoprotein	  A33,	  including	  50%	  of	  pancreatic	  cancers,	  pancreatic	  ductal	  adenocarcinomas	  among	  them.13	  CHO	  antibodies	  are	  a	  relatively	  new	  class	  of	  chimeric	  or	  humanized	  IgG	  antibodies	  raised	  from	  FDA	  approved	  Chinese	  hamster	  ovary	  cells,	  commonly	  used	  for	  raising	  antibodies,	  that	  show	  great	  promise	  for	  therapeutic	  work.25	  For	  example,	  CHO	  antibodies	  have	  a	  ten	  day	  half-­‐life	  within	  the	  human	  body	  and	  are	  ten	  times	  more	  selective	  for	  diseased	  tissue	  than	  healthy	  tissue.25	  However,	  it	  is	  important	  to	  note	  that	  CHO	  31.1,	  an	  IgG	  class	  antibody,	  is	  significantly	  larger	  than	  avidin,	  as	  seen	  in	  Figure	  5,	  and	  we	  will	  likely	  need	  to	  limit	  the	  number	  of	  antibodies	  on	  the	  surface	  to	  reduce	  steric	  hindrance	  of	  treatment	  molecules.	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Figure	  5:	  Comparison	  of	  biotin,	  avidin,	  and	  antibody.	  One	  dimer	  of	  avidin,	  our	  linker	  molecule,	  is	  shown	  in	  green,	  with	  a	  magenta	  biotin	  bound	  in	  the	  right	  corner.	  For	  comparison,	  an	  IgG	  antibody	  is	  shown	  in	  blue	  to	  the	  left.	  Figure	  was	  generated	  in	  MacPyMOL,	  PDB	  files	  1avd	  and	  1igt.	  	   	  Targeting	  glycoprotein	  A33	  is	  not	  only	  useful	  as	  a	  way	  of	  differentiating	  between	  healthy	  and	  tumorous	  tissue;	  it	  has	  been	  found	  that	  protein	  binding	  activity	  on	  gpA33	  could	  be	  the	  key	  to	  cellular	  uptake	  of	  desired	  nanovehicles.12	  In	  2008,	  Frey	  et	  al.	  found	  that	  when	  antibodies	  bound	  gpA33,	  they	  triggered	  an	  endocytotic	  event,	  bringing	  the	  entire	  antibody-­‐receptor	  complex	  into	  the	  cell	  via	  vesicles.13	  This	  internalization	  is	  an	  additional	  benefit	  of	  its	  use	  in	  our	  nanovehicle,	  as	  gpA33	  binding	  provides	  an	  entryway	  into	  cancerous	  cells,	  rather	  than	  simply	  binding	  the	  outside.	  In	  addition,	  gpA33	  is	  trafficked	  through	  the	  cell	  before	  being	  recycled	  to	  the	  surface	  again,	  providing	  particles	  with	  both	  time	  for	  treatments	  to	  be	  triggered	  and	  a	  renewable	  target.13	  	   The	  internalization	  of	  our	  biomarker	  is	  a	  key	  factor	  for	  choosing	  gpA33	  as	  a	  molecular	  target,	  and	  makes	  the	  choice	  of	  treatment	  possible.	  The	  final	  step	  to	  constructing	  our	  nanovehicle	  is	  the	  addition	  of	  a	  treatment	  method,	  but	  rather	  than	  conjugating	  a	  drug	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to	  the	  surface	  of	  our	  nanoparticles,	  we	  have	  opted	  to	  load	  our	  particles	  with	  boron-­‐10	  for	  the	  purposes	  of	  performing	  boron-­‐neutron	  capture	  therapy.	  Boron-­‐neutron	  capture	  therapy,	  or	  BNCT,	  was	  first	  theorized	  as	  a	  treatment	  in	  1936	  by	  G.L	  Locher	  at	  the	  Franklin	  Institute,	  and	  remained	  purely	  theoretical	  for	  several	  years.26	  BNCT	  works	  by	  introducing	  a	  large	  payload	  of	  boron-­‐10,	  a	  common	  and	  typically	  stable	  isotope	  of	  boron,	  into	  targeted	  tissue.	  Boron-­‐10	  is	  unique	  in	  that	  it	  is	  highly	  capable	  of	  capturing	  thermal	  neutrons	  and	  promptly	  undergoing	  nuclear	  decay,	  as	  seen	  in	  Figure	  6.27	  Upon	  capture	  of	  a	  thermal	  neutron,	  boron-­‐10	  would	  convert	  to	  boron-­‐11	  before	  undergoing	  decay	  into	  lithium-­‐7,	  releasing	  both	  alpha	  particles	  and	  gamma	  radiation	  known	  as	  linear	  energy	  transfer	  (LET).27,28	  The	  majority	  of	  the	  damage	  caused	  by	  the	  resulting	  radiation	  would	  occur	  within	  approximately	  10	  micrometers	  of	  the	  boron-­‐10	  nucleus,	  approximately	  the	  diameter	  of	  cancer	  cells,	  because	  alpha	  radiation	  is	  short-­‐range	  but	  high	  energy.27,28	  BNCT	  was	  first	  developed	  in	  1952,	  when	  it	  was	  found	  that	  boron-­‐rich	  compounds	  concentrated	  in	  cancerous	  brain	  tissue	  over	  healthy	  brain	  tissue.	  This	  finding	  paved	  the	  way	  for	  clinical	  trials	  of	  BNCT	  to	  treat	  brain	  cancers	  throughout	  the	  1950s.27,29	  Unfortunately,	  researchers	  found	  that	  they	  could	  not	  produce	  sufficiently	  high	  concentrations	  of	  boron-­‐10	  within	  diseased	  tissue	  while	  simultaneously	  avoiding	  healthy	  tissue,	  and	  so	  trials	  stopped	  in	  1961.	  	  Efforts	  restarted	  in	  the	  1980s	  and	  1990s	  to	  treat	  glioblastoma	  mulitforme,	  but	  with	  similar	  results.30	  However,	  researchers	  were	  able	  to	  determine	  that	  BNCT	  could	  only	  be	  effective	  with	  concentrations	  of	  109	  atoms	  per	  cell,	  or	  20	  micrograms	  per	  gram	  of	  tumor.28	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Figure	  6:	  The	  boron-­‐neutron	  capture	  reaction.	  	   To	  achieve	  therapeutic	  concentrations	  of	  boron-­‐10	  in	  the	  cell,	  scientists	  began	  investigating	  new	  boron-­‐10	  rich	  molecules	  for	  BNCT.	  For	  example,	  Sano	  and	  colleagues	  began	  working	  on	  boron-­‐enriched	  streptavidin	  as	  a	  macromolecular	  carrier	  of	  boron-­‐10.28	  Macromolecular	  boron-­‐10	  carriers	  would	  be	  useful	  as	  multifunctional	  pieces	  of	  therapy,	  either	  on	  nanoparticles	  or	  therapeutic	  antibodies.31	  Our	  nanovehicle	  uses	  a	  biotinylated	  boron-­‐10	  rich	  polymer,	  polyGL,	  as	  a	  payload	  for	  BNCT.	  PolyGL	  is	  a	  repeating	  peptide	  of	  D-­‐glutamate	  and	  D-­‐lysine	  of	  a	  molecular	  weight	  of	  20,000–50,000	  Daltons,	  which	  can	  be	  loaded	  with	  sodium	  mercaptoundecahydrododecaborate	  (BSH),	  a	  common	  boron	  cage	  that	  is	  often	  used	  for	  BNCT	  trials.28,31	  BSH	  is	  conjugated	  to	  lysine	  residues	  in	  polyGL,	  of	  which	  there	  are	  anywhere	  from	  136	  to	  341	  per	  polyGL	  molecule,	  on	  average.	  	  	   All	  together,	  our	  targeted	  nanovehicle	  (Figure	  2)	  will	  be	  able	  to	  safely	  travel	  through	  the	  body	  thanks	  to	  a	  PEG	  coating,	  with	  the	  ability	  to	  selectively	  bind	  pancreatic	  ductal	  adenocarcinomas.	  Upon	  reaching	  the	  PDAC	  cells,	  targeting	  antibodies	  will	  complex	  with	  gpA33	  and	  trigger	  internalization.	  Particle	  location	  will	  be	  tracked	  with	  MRI,	  so	  that	  upon	  concentration	  in	  pancreatic	  tumors,	  the	  area	  could	  be	  irradiated	  with	  thermal	  neutron	  beams,	  beginning	  BNCT.	  We	  expect	  that	  this	  treatment	  will	  provide	  a	  safer	  and	  more	  selective	  form	  of	  cancer	  treatment	  for	  a	  disease	  that	  has	  been	  historically	  challenging.	  We	  hope	  to	  be	  able	  to	  provide	  a	  better	  prognosis	  for	  pancreatic	  cancer	  patients	  than	  is	  currently	  available,	  improving	  both	  the	  length	  and	  quality	  of	  life	  for	  cancer	  patients.	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   My	  goal	  with	  this	  project	  was	  to	  complete	  the	  functionalization	  of	  the	  nanoparticle	  surface,	  including	  both	  antibodies	  and	  polyGL.	  In	  moving	  toward	  this	  goal,	  I	  have	  worked	  to	  accomplish	  the	  following	  objectives:	  (1) ensure	  that	  our	  avidin	  linkers	  are	  bound	  to	  biotin-­‐PEG	  and	  remain	  capable	  of	  binding	  additional	  biotins,	  relying	  primarily	  on	  a	  magnetic	  pull-­‐down	  assay;	  (2) biotinylate	  both	  targeting	  antibodies	  and	  polyGL;	  	  (3) bind	  antibodies	  to	  the	  surface	  of	  gold	  nanoparticles	  and	  quantify	  the	  number	  of	  antibodies	  per	  particle;	  and	  	  (4) conjugate	  PolyGL	  to	  the	  avidin	  and	  monitor	  its	  presence,	  through	  studies	  of	  particle	  surface	  charge	  and	  fluorescence	  based	  protein	  quantification	  assays.	  	  In	  this	  way,	  the	  functionalization	  of	  gold	  nanoparticles	  to	  target	  and	  treat	  pancreatic	  cancer	  is	  well	  underway	  and	  approaching	  testing	  for	  overall	  functionality	  of	  the	  nanovehicle	  as	  a	  whole.	  In	  the	  subsequent	  chapters,	  I	  will	  describe	  both	  the	  experimental	  procedures	  and	  initial	  results	  I	  have	  obtained	  toward	  meeting	  these	  objectives.	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Materials	  and	  Methods	  
	   All	  glassware	  used	  for	  synthesis	  in	  this	  study	  was	  cleaned	  with	  aqua	  regia	  (3:1	  concentrated	  HCl:	  HNO3)	  and	  all	  aqueous	  solutions	  were	  prepared	  with	  “nanopure”	  water	  (nH2O),	  purified	  to	  18.2	  MΩxcm	  resistivity	  using	  a	  Barnstead	  Nanopure	  Ultrapure	  Water	  system.	  Phosphate	  buffered	  saline,	  used	  to	  assess	  stability	  of	  nanoparticles	  in	  in	  vitro	  conditions,	  was	  prepared	  with	  100	  mM	  phosphate	  and	  150	  mM	  NaCl	  from	  sodium	  chloride,	  sodium	  hypochlorate,	  and	  potassium	  hypochlorate	  in	  nanopure	  water	  and	  adjusted	  to	  pH	  7.3	  with	  1	  M	  hydrochloric	  acid	  or	  sodium	  hydroxide.	  	  Alternatively,	  phosphate	  buffers	  without	  saline	  were	  prepared	  for	  several	  assays.	  For	  Zeta-­‐Potential,	  a	  50	  mM	  phosphate	  buffer	  at	  pH	  7.2	  was	  prepared	  to	  reduce	  the	  activity	  of	  analyzed	  samples.	  Phosphate	  buffer	  with	  a	  pH	  6.5	  was	  prepared	  from	  30	  mM	  potassium	  phosphate	  monobasic	  (Sigma-­‐Aldrich)	  and	  30	  mM	  sodium	  phosphate	  dibasic	  for	  biotinylation	  reactions.	  	  	  Gold	  nanoparticles	  were	  synthesized	  to	  11.2	  nm	  using	  50	  mL	  of	  1	  mM	  potassium	  gold	  (III)	  chloride	  and	  10	  mL	  of	  38.8	  mM	  sodium	  citrate	  tribasic	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO)	  as	  per	  the	  procedure	  described	  in	  Flynn	  and	  Gerwith.32	  A	  1:1	  mixture	  of	  polyethylene	  glycol	  (PEG)	  linkers	  was	  used	  for	  functionalization	  of	  gold	  nanoparticles,	  including	  carboxylic	  acid-­‐PEG-­‐thiol	  (MW=3500	  g/mol)	  and	  biotin-­‐PEG-­‐thiol	  (MW=5000	  g/mol);	  carboxy-­‐PEG-­‐thiol	  biotin-­‐PEG-­‐thiol	  was	  purchased	  from	  NANOCS	  (New	  York,	  NY).	  Avidin	  functionalization	  was	  performed	  with	  avidin	  from	  Pierce	  (Rockford,	  IL),	  used	  as	  received.	  	  	  Stability	  and	  size	  of	  all	  nanoparticle	  samples	  were	  assessed	  with	  UV-­‐visible	  spectroscopy	  (UV-­‐vis)	  and	  Dynamic	  Light	  Scattering	  (DLS).	  UV-­‐vis	  spectra	  were	  acquired	  at	  a	  1:10	  dilution	  in	  nanopure	  water	  or	  PBS	  on	  a	  Varian	  Cary	  500	  or	  Cary	  100	  Scan	  UV-­‐Visible-­‐NIR	  spectrophotometer	  in	  a	  1-­‐cm	  path-­‐length	  cell.	  These	  spectrophotometers	  use	  a	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double-­‐beam	  configuration	  and	  solvent	  baselines	  were	  taken	  concurrently	  with	  experimental	  scans	  at	  a	  rate	  of	  600.00	  nm/min.	  Spectra	  were	  recorded	  from	  300	  to	  700	  nm,	  with	  bare	  gold	  nanoparticles	  typically	  showing	  a	  peak	  at	  519	  nm	  and	  an	  absorbance	  at	  or	  around	  0.3	  absorbance	  units.	  	  DLS	  was	  performed	  on	  particles	  dispersed	  with	  the	  use	  of	  a	  Branson	  Sonifier	  250	  ultrasonic	  horn	  (VWR	  Scientific)	  at	  10%	  duty	  cycle	  and	  Output	  Control	  of	  1-­‐2.	  Samples	  were	  filtered	  through	  a	  25	  mm	  syringe	  filter	  with	  a	  0.45	  μm	  cellulose	  acetate	  membrane.	  Measurements	  were	  taken	  with	  a	  Malvern	  Zetasizer	  Nano-­‐2S	  instrument	  using	  Zetasizer	  software	  6.0.1	  in	  four-­‐sided	  clear	  plastic	  fluorescence	  cuvettes.	  The	  settings	  are	  described	  in	  Table	  1;	  samples	  were	  thermally	  equilibrated	  for	  two	  minutes	  prior	  to	  experimental	  measurements.	  
Table	  1:	  Dynamic-­‐light	  scattering	  parameters.	  Dispersant	   Water,	  PBS,	  or	  phosphate	  buffer	  Dispersant	  Viscosity	  (cP)	   0.8872	  Dispersant	  Refractive	  Index	   1.330	  Material	  Refractive	  Index	   1.650	  Material	  Absorption	   0.20	  Temperature	   25°C	  	  
Functionalization	  Dissolving	  1	  mg/mL	  C-­‐PEG	  and	  1.44	  mg/mL	  B-­‐PEG	  in	  1	  mL	  of	  nanopure	  water	  and	  adding	  this	  solution	  dropwise	  to	  stirring	  gold	  nanoparticles	  set	  up	  addition	  of	  C-­‐PEG	  and	  B-­‐PEG	  to	  bare	  gold	  nanoparticles	  in	  a	  1:1	  ratio.	  Subsequently,	  avidin	  was	  added	  to	  PEGylated	  particles	  at	  a	  concentration	  of	  0.1	  mg/mL,	  first	  dissolved	  in	  0.5	  mL	  nanopure	  water.	  	  
Purification	  of	  Gold	  Nanoparticles	  	   Following	  any	  functionalization	  step,	  particles	  were	  purified	  through	  centrifugation.	  Over	  the	  course	  of	  this	  study,	  several	  centrifuges	  were	  utilized.	  Five	  milliliter	  or	  higher	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volume	  samples	  were	  centrifuged	  in	  50	  mL	  Nalgene	  Oak	  Ridge	  polypropylene	  copolymer	  centrifuge	  tubes.	  In	  a	  ThermoScientific	  Lynx	  centrifuge	  with	  an	  A27-­‐6×50	  rotor,	  samples	  were	  balanced	  to	  within	  0.05	  g	  and	  spun	  at	  43,378	  g	  for	  25	  minutes.	  This	  was	  repeated	  three	  times,	  washing	  with	  3	  mL	  of	  PBS	  or	  10%	  PBS	  after	  each	  round.	  In	  a	  Sorvall	  Legend	  XLR	  centrifuge,	  samples	  were	  spun	  for	  35–45	  minutes,	  depending	  on	  volume,	  at	  22,269	  g	  three	  times,	  washing	  with	  3	  mL	  10%	  PBS	  each	  round.	  Small	  volume	  samples	  and	  the	  supernatant	  from	  standing	  or	  table–top	  centrifugation	  were	  purified	  with	  microcentrifuges	  in	  1.7	  mL	  Eppendorf	  tubes	  at	  16,000	  g	  for	  20	  minutes.	  This	  was	  also	  repeated	  three	  times	  and	  washed	  with	  10%	  PBS.	  
Biotinylated	  Magnetic	  Beads	  Assay	  Presence	  and	  functionality	  of	  avidin	  were	  assessed	  with	  a	  biotinylated	  magnetic	  bead	  assay,	  using	  10	  μm	  magnetic	  beads	  purchased	  from	  Spherotech	  (Lake	  Forest,	  IL).	  	  Avidin-­‐functionalized	  PEGylated	  AuNPs	  were	  diluted	  1:10,	  matching	  standard	  solutions	  made	  for	  UV-­‐Vis	  spectroscopy,	  and	  biotinylated-­‐magnetic	  beads	  were	  added	  to	  a	  concentration	  of	  100	  binding	  sites/avidin	  and	  shaken	  overnight.	  	  Solutions	  were	  then	  left	  to	  collect	  on	  a	  magnet,	  typically	  on	  the	  top,	  for	  another	  24	  hours	  before	  solutions	  were	  collected	  into	  5	  mL	  micro	  fluorescence	  cuvettes	  and	  absorbances	  were	  measured	  between	  300	  nm	  and	  700	  nm	  on	  a	  UV-­‐Vis	  spectrometer.	  The	  absorbance	  of	  the	  characteristic	  peak	  of	  our	  gold	  nanoparticles	  around	  520	  nm	  indicated	  the	  extent	  to	  which	  avidinated	  nanoparticles	  were	  collected	  from	  the	  solution	  by	  biotinylated	  magnetic	  beads.	  
Antibody	  Modification	  As33	  biotinylation	  was	  initially	  performed	  using	  a	  Chromalink©	  Biotin	  Antibody	  Labeling	  Kit	  (B-­‐9007-­‐105K)	  produced	  by	  Solulink	  (San	  Diego,	  CA).	  A	  secondary	  antibody	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conjugation	  method	  was	  selected	  to	  ensure	  a	  more	  accessible	  terminal	  biotin	  for	  avidin	  binding,	  through	  the	  use	  of	  a	  longer	  linker.	  100	  μg	  of	  antibody	  (1	  mg/mL	  in	  0.1	  M	  sodium	  phosphate	  buffer)	  was	  reacted	  in	  the	  dark	  with	  10	  μL	  of	  0.1	  M	  sodium	  periodate	  (23	  mg/mL)	  for	  30	  minutes.	  Reaction	  was	  quenched	  with	  500	  μL	  of	  1	  ×	  PBS	  (pH	  7.4)	  and	  the	  presence	  of	  aldehydes	  was	  detected	  using	  a	  Purpald	  assay.	  Purpald	  assay	  was	  performed	  with	  a	  1:3	  ratio	  of	  antibody	  solution	  to	  Purpald	  solution	  (10	  mg/mL	  in	  1	  N	  NaOH);	  a	  color	  change	  of	  clear	  to	  deep	  pink	  or	  purple	  in	  under	  5	  minutes	  indicates	  the	  presence	  of	  aldehydes,	  and	  that	  the	  reaction	  may	  proceed.	  	  A	  2	  μL	  solution	  of	  50	  mM	  hydrazide	  linker	  stock	  (Hydraxine-­‐PEG4-­‐Biotin	  in	  ethanol)	  was	  added	  to	  the	  antibody	  stock	  and	  incubated	  for	  one	  hour	  at	  room	  temperature.	  At	  the	  end	  of	  an	  hour,	  the	  reaction	  was	  quenched	  with	  1	  mL	  40	  mM	  HEPES	  buffer	  (pH	  8.5)	  and	  concentrate	  to	  300	  μL,	  approximately	  30	  minutes	  in	  an	  Amicon	  filter	  (Millipore	  BioMax	  5k	  NMWL)	  in	  a	  swinging	  bucket	  rotor	  at	  4,000g.	  Solution	  was	  adjusted	  to	  1	  mL	  with	  40	  mM	  HEPES	  buffer	  and	  stored	  at	  4°C.	  	  This	  method	  was	  utilized	  to	  add	  both	  PEG-­‐biotin	  and	  PEG-­‐thiol	  linkers	  to	  antibodies	  through	  hydrazine	  reactions,	  to	  conjugate	  antibodies	  either	  through	  biotin-­‐avidin	  interactions	  or	  direct	  linkage	  to	  the	  gold	  surface.	  Direct	  linkage	  could	  be	  monitored	  through	  a	  5	  nm	  shift	  in	  the	  UV-­‐visible	  spectrum	  for	  these	  gold	  nanoparticles,	  which	  was	  measured	  using	  a	  Nanodrop	  before	  backfilling	  with	  a	  1:1	  mixture	  of	  C-­‐PEG	  and	  B-­‐PEG.	  
Dot	  Immunoblot	  Assays	  (Dot-­‐blots)	  Success	  of	  biotinylation	  was	  measured	  through	  dot	  immunoassays,	  or	  “dot-­‐blots”.	  	  Biotinylated	  As33	  was	  spotted	  onto	  a	  nitrocellulose	  membrane	  in	  concentrations	  ranging	  from	  20	  μg	  to	  1.25	  μg,	  which	  was	  incubated	  for	  one	  hour	  in	  15	  mL	  blocking	  buffer	  (5%	  Blotting-­‐Grade	  Blocker	  (Bio-­‐Rad	  #170-­‐6404)	  in	  Tris-­‐buffered	  saline	  (TBS))	  for	  at	  least	  one	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hour	  at	  room	  temperature.	  Samples	  were	  then	  incubated	  in	  1:1000	  dilution	  of	  horseradish	  peroxidase	  conjugated	  anti-­‐biotin	  antibody	  in	  blocking	  buffer	  for	  one	  hour	  at	  room	  temperature	  with	  shaking.	  	  Excess	  block	  and	  antibody	  were	  removed	  through	  washes	  with	  wash	  buffer	  (0.05%	  Tween	  20	  in	  TBS).	  Chemiluminescent	  visualization	  of	  HRP-­‐tagged	  antibodies	  was	  stimulated	  with	  chemiluminescent	  substrate	  (Luminol	  Denville	  Scientific	  Inc	  E2400)	  and	  read	  on	  a	  BioRad	  GelDoc	  XR	  imager	  (100	  second	  exposure	  on	  chemiluminescent	  protocol,	  10	  images).	  	  Antibody	  addition	  to	  nanoparticles	  was	  also	  assessed	  with	  dot	  immunoassays,	  with	  secondary	  antibody	  treatment	  varying	  based	  on	  the	  identity	  of	  antibody	  added.	  As33	  was	  tagged	  with	  goat	  anti-­‐mouse	  horseradish	  peroxidase	  conjugated	  secondary	  antibodies	  in	  a	  concentration	  of	  1:5000.	  Nanoparticles	  were	  functionalized	  with	  antibodies	  either	  through	  addition	  of	  0.5	  mg/mL	  As33	  to	  0.5	  mg/mL	  avidin	  solution,	  which	  was	  then	  added	  directly	  to	  5	  mL	  of	  PEG-­‐coated	  gold	  nanoparticles,	  or	  through	  addition	  of	  0.05	  mg/mL	  As33	  to	  5	  mL	  Avidin/PEG-­‐coated	  gold	  nanoparticles.	  Potential	  quenching	  was	  assessed	  through	  dot	  blots	  on	  which	  gold	  nanoparticles	  and	  antibodies	  were	  overlaid	  but	  not	  mixed	  or	  mixed	  1:1.	  
Enzyme-­‐Linked	  Immunosorbent	  Assays	  Enzyme-­‐linked	  immunosorbent	  assays,	  or	  ELISAs,	  optimized	  by	  Harini	  Natarajan	  ’15,	  were	  run	  on	  antibody	  conjugated	  gold	  nanoparticles.	  Several	  96-­‐well	  microtiter	  plates	  were	  coated	  overnight	  with	  protein	  A.	  Plates	  were	  washed	  (3	  times)	  with	  TBS	  and	  blocked	  with	  blocking	  buffer	  (2%	  BSA	  in	  TBST)	  and	  incubated	  for	  one	  hour.	  A33	  antibody	  samples	  were	  diluted	  to	  approximately	  1	  μg/mL	  and	  then	  diluted	  1:2	  across	  the	  plate	  in	  triplicate	  to	  create	  a	  standard	  curve;	  antibody	  conjugated	  particles	  at	  approximately	  an	  optical	  density	  of	  1(1	  OD)	  were	  also	  plated	  in	  1:2	  serial	  dilutions	  and	  the	  plate	  was	  incubated	  for	  an	  hour.	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B-­‐PEG	  was	  targeted	  and	  identified	  with	  1:5000	  Neutravidin-­‐HRP	  secondary	  antibody	  for	  one	  hour.	  Wells	  were	  aspirated	  and	  100	  uL	  of	  TMB	  (0.4	  g/L	  3,3’,5,5’-­‐tetramethylbenzidine)	  was	  added	  to	  each	  well.	  Upon	  color	  change,	  the	  reaction	  was	  stopped	  with	  100	  μL	  of	  2	  M	  H2SO4.	  Plates	  were	  analyzed	  with	  UV-­‐Vis	  scanning	  at	  450	  nm	  on	  a	  microplate	  reader	  (Spectra	  Max	  M3	  from	  Molecular	  Devices)	  and	  analyzed	  in	  Excel.	  
Biotinylation	  of	  polyGL	  	   Biotinylation	  of	  polyGL	  was	  performed	  following	  a	  procedure	  optimized	  by	  Sara	  Althari	  ’13	  for	  her	  thesis.33	  A	  10	  mg	  sample	  polyGL	  was	  reacted	  with	  2.5	  μL	  of	  10	  mM	  biotin-­‐sulfo-­‐NHS	  for	  24	  hours	  at	  4°C.	  Samples	  were	  then	  filtered	  in	  10,000	  Dalton	  cut-­‐off	  spin	  columns	  and	  resuspended	  in	  1	  mL	  of	  pH	  6.4	  phosphate	  buffer.	  Biotinylation	  was	  monitored	  with	  dot-­‐blots.	  
Biotin	  Quantification	  using	  Quant*Tag	  	   Biotin	  quantification	  was	  measured	  with	  the	  Quant*Tag	  kit,	  following	  manufacturer’s	  instructions	  (Chromalink	  Quant*Tag	  Protein	  Quantification	  Kit).	  Standard	  curves	  of	  free	  biotin	  were	  used	  to	  correlate	  assay	  absorbance	  with	  biotin	  concentration.	  Absorbance	  measurements	  were	  monitored	  at	  535	  nm	  with	  a	  Spectra	  Max	  M3	  (Molecular	  Devices)	  microplate	  reader.	  	  
Addition	  of	  polyGL	  to	  Avidinated	  Gold	  Nanoparticles	  	   After	  biotinylation,	  polyGL	  was	  added	  at	  a	  concentration	  of	  2	  mg/mL	  to	  avidin	  functionalized	  particles	  and	  stirred	  overnight.	  	  
Zeta-­‐Potential	  	   In	  order	  to	  measure	  the	  surface	  charge	  of	  functionalized	  gold	  nanoparticles	  at	  various	  stages,	  we	  used	  the	  Zeta-­‐Potential	  function	  of	  a	  Zetasizer	  Nano™	  by	  Malvern	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Instruments.	  Measurements	  were	  run	  at	  1:200	  dilutions	  of	  all	  functionalized	  particles	  in	  nanopure	  water,	  to	  maintain	  the	  conductivity	  of	  samples	  within	  the	  functional	  range	  of	  Zeta-­‐Potential	  settings.	  Approximately	  1	  mL	  of	  sample	  was	  analyzed	  in	  disposable	  folded	  capillary	  cells	  (DTS1070	  from	  Malvern,	  Inc.)	  using	  the	  settings	  listed	  in	  Table	  2.	  	  Cuvettes	  were	  washed	  with	  ethanol,	  air-­‐dried,	  and	  rinsed	  with	  nanopure	  water	  before	  each	  use.	  Data	  was	  fit	  using	  the	  Smoluchowski	  model.	  	  
	  
Table	  2:	  Zeta-­‐potential	  parameters.	  Sample	  material	   Gold	  Sample	  refractive	  index	   1.650	  Sample	  absorption	   0.20	  Dispersant	   Water,	  50	  mM	  phosphate	  buffer	  Dispersant	  viscosity	  (cP)	   0.8872	  Dispersant	  refractive	  index	   1.330	  Dielectric	  constant	   78.5	  	  
Gel	  Electrophoresis	  	   Gel	  electrophoresis	  was	  used	  to	  further	  assess	  particle	  functionalization	  and	  shifts	  in	  particle	  properties.	  This	  procedure	  was	  modified	  from	  Doane.34	  Particles	  were	  concentrated	  to	  about	  14	  OD	  and	  mixed	  1:1	  with	  50%	  glycerol	  before	  being	  loaded	  into	  a	  1%	  agarose	  gel.	  Samples	  were	  run	  in	  0.75xTAE	  buffer	  for	  1.5	  hours	  at	  80	  V	  from	  centrally	  placed	  lanes.	  Because	  of	  the	  characteristic	  deep	  red	  color	  of	  AuNPs,	  no	  dye	  was	  necessary	  to	  visualize	  the	  bands	  on	  these	  gels.	  Images	  were	  taken	  on	  a	  BioRad	  ChemDoc	  gel	  imager	  using	  ImageLab	  software	  with	  transmitted	  light.	  	  
CBQCA	  Protein	  Quantification	  Assay	  	   Quantification	  of	  avidin	  and	  polyGL	  concentration	  on	  the	  surface	  of	  our	  particles	  was	  performed	  using	  a	  CBQCA	  Protein	  Quantification	  kit	  from	  Molecular	  Probes	  following	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manufacturer’s	  instructions.	  The	  kit	  was	  thoroughly	  tested	  against	  nanoparticle	  and	  protein	  controls	  to	  determine	  and	  account	  for	  gold	  nanoparticle	  assay	  interference.	  Standard	  curves	  of	  free	  avidin	  and	  polyGL	  ranging	  from	  0–1000	  ng	  were	  run	  for	  quantification,	  with	  methoxy-­‐PEG-­‐thiol	  coated	  nanoparticles	  (M-­‐PEG	  AuNPs)	  added	  at	  working	  concentrations	  of	  experimental	  conditions	  to	  account	  for	  fluorescence	  quenching,	  a	  common	  property	  of	  gold	  nanoparticles.	  Nanoparticle	  concentrations	  were	  obtained	  through	  UV-­‐visible	  spectroscopy	  and	  concentrations	  were	  standardized	  in	  all	  experimental	  and	  control	  settings.	  	  Fluorescence	  emission	  was	  taken	  on	  a	  plate	  reader	  (Spectra	  Max	  M3	  from	  Molecular	  Devices)	  at	  an	  excitation	  wavelength	  of	  460	  nm	  and	  emission	  monitored	  at	  550	  nm.	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Results	  and	  Discussion	  	  
Assessment	  of	  AuNPs	  Functionalized	  with	  PEG	  Derivatives	  	   The	  first	  step	  in	  preparing	  gold	  nanovehicles	  is	  providing	  a	  full	  coat	  of	  PEG	  for	  stability	  and	  further	  linkages.	  	  PEG	  is	  added	  at	  a	  concentration	  of	  about	  2	  mg/mL.35	  The	  procedures	  for	  PEGylation	  were	  carried	  out	  following	  the	  work	  of	  established	  lab	  protocols,	  and	  yielded	  the	  same	  results	  in	  spectroscopy	  and	  DLS.35	  As	  seen	  in	  Figures	  7	  and	  8,	  bare	  AuNPs	  are	  approximately	  11.2	  nm	  in	  diameter	  and	  have	  a	  maximum	  UV-­‐vis	  absorbance	  peak	  at	  519	  nm.	  The	  addition	  of	  C-­‐PEG/B-­‐PEG	  increases	  the	  size	  from	  11.2	  nm	  to	  approximately	  32	  nm	  and	  causes	  a	  red	  shift	  in	  UV-­‐vis	  to	  521	  nm.	  	  C-­‐PEG	  and	  B-­‐PEG	  are	  conjugated	  to	  gold	  nanoparticles	  in	  a	  1:1	  ratio,	  where	  C-­‐PEG	  is	  used	  to	  make	  the	  particle	  surface	  negative	  to	  minimize	  non-­‐specific	  adsorption	  to	  cell	  surfaces.	  Biotin-­‐PEG	  serves	  as	  the	  linkage	  point	  for	  avidin	  molecules,	  the	  “molecular	  glue”	  of	  this	  system.	  In	  addition,	  anti-­‐biotin	  dot	  immunoblot	  assays	  were	  performed	  on	  these	  particles	  to	  confirm	  the	  presence	  of	  biotin.	  A	  positive	  result	  with	  this	  assay	  (data	  not	  shown)	  confirms	  the	  presence	  of	  biotin	  in	  the	  PEG	  coat.	  	  Zeta-­‐potential	  measurements	  were	  used	  to	  probe	  changes	  in	  surface	  charge.	  Addition	  of	  C-­‐PEG/B-­‐PEG	  to	  the	  AuNPs	  caused	  a	  shift	  from	  –48	  mV	  for	  bare	  AuNPs	  to	  approximately	  –40	  mV.	  This	  shift	  in	  charge	  indicates	  that	  there	  are	  negatively	  charged	  moieties	  present	  on	  the	  gold	  surface,	  but	  not	  as	  many	  as	  “bare”	  gold	  nanoparticles.	  Bare	  gold	  nanoparticles	  are,	  in	  fact,	  coated	  with	  citrate	  ions	  when	  first	  synthesized,32	  and	  C-­‐PEG/B-­‐PEG	  functionalization	  displaces	  these	  ions.	  B-­‐PEG	  is	  uncharged,	  but	  C-­‐PEG	  carries	  a	  net	  negative	  charge;	  therefore,	  the	  overall	  negative	  charge	  indicates	  that	  C-­‐PEG	  is	  now	  bound	  to	  the	  surface,	  to	  contribute	  to	  a	  net	  negative	  charge.	  The	  change	  in	  magnitude	  of	  the	  charge	  most	  likely	  arises	  from	  the	  presence	  of	  B-­‐PEG,	  which	  limits	  the	  number	  of	  C-­‐PEG	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polymers	  on	  the	  surface,	  so	  the	  surface	  is	  not	  saturated	  with	  negative	  charge,	  as	  it	  is	  in	  the	  citrate-­‐coated	  form.	  	  
Avidin	  Conjugation	  and	  Assessment	  of	  Avidin	  AuNPs	  Once	  the	  particles	  have	  a	  coating	  of	  PEG,	  avidin	  is	  added	  to	  form	  a	  conjugation	  point	  for	  targeting	  and	  treatment	  molecules.	  Unbound	  avidin,	  with	  a	  molecular	  weight	  of	  about	  66,000	  g/mol,	  was	  analyzed	  through	  DLS.	  The	  size	  of	  avidin	  was	  about	  6	  nm	  (data	  not	  shown).	  Figure	  7	  shows	  the	  UV-­‐vis	  spectral	  change	  resulting	  from	  avidin	  addition.	  A	  2	  nm	  shift	  in	  peak	  position,	  from	  521	  nm	  to	  523	  nm,	  on	  average,	  is	  observed.	  Continued	  reduction	  in	  peak	  height	  was	  also	  observed,	  and	  attributed	  to	  loss	  from	  purification.	  Here	  an	  estimated	  total	  yield	  of	  77%	  is	  seen,	  based	  simply	  on	  maximal	  peak	  height.	  Figure	  8	  contains	  th	  DLS	  particle	  number	  size	  distribution	  following	  avidin	  addition.	  A	  6	  nm	  change,	  to	  38	  nm,	  is	  seen	  with	  the	  avidin	  exposure.	  This	  result	  indicates	  a	  significant	  but	  incomplete	  coating	  of	  avidin	  around	  the	  particles.	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Figure	  7:	  UV-­‐visible	  spectroscopy	  of	  functionalized	  gold	  nanoparticles.	  Particle	  solutions	  diluted	  by	  a	  factor	  of	  ten	  were	  analyzed	  with	  a	  Cary	  500	  UV-­‐visible	  spectrometer	  from	  300–700	  nm.	  Typically,	  bare	  11.2	  nm	  gold	  nanoparticles	  (black	  line)	  absorb	  at	  approximately	  519	  nm.	  The	  addition	  of	  PEG	  causes	  a	  red	  shift	  to	  approximately	  521	  nm	  (red	  line),	  and	  avidin	  addition	  typically	  results	  in	  peaks	  at	  523	  nm	  (blue	  line).	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Figure	  8:	  Dynamic	  light	  scattering	  of	  functionalized	  AuNPs.	  Number	  particle	  size	  distributions	  are	  for	  bare	  (black	  line),	  C-­‐PEG/B-­‐PEG	  coated	  (red	  line)	  and	  avidin	  functionalized	  (blue	  line)	  AuNPs.	  Measurements	  were	  taken	  on	  a	  ZetaSizer	  Nano2000	  from	  Malvern	  Instruments.	  	   Ensuring	  that	  avidin	  remained	  capable	  of	  binding	  biotin	  after	  being	  conjugated	  to	  PEGylated	  AuNPs	  was	  critical	  to	  subsequent	  steps	  in	  developing	  the	  nanovehicle.	  A	  biotinylated	  magnetic	  bead	  “pull-­‐down”	  assay	  allowed	  us	  to	  probe	  the	  ability	  of	  the	  immobilized	  avidin	  on	  the	  AuNPs	  to	  bind	  biotin.	  Figure	  9	  is	  the	  UV-­‐visible	  spectrum	  of	  functionalized	  AuNPs	  exposed	  to	  biotinylated	  magnetic	  beads,	  which	  could	  bind	  avidin.	  The	  magnetic	  beads	  were	  removed	  from	  solution	  after	  a	  24	  hour	  incubation	  with	  functionalized	  AuNPs.	  Figure	  9	  shows	  the	  spectra	  of	  C-­‐PEG/B-­‐PEG	  AuNPs,	  avidin	  AuNPs,	  and	  blocked-­‐avidin	  AuNPs	  (three	  of	  the	  four	  biotin	  binding	  sites	  are	  blocked	  before	  immobilizing	  on	  particles)	  after	  exposure	  to	  biotinylated	  magnetic	  beads.	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Figure	  9:	  Biotinylated	  magnetic	  bead	  assay	  for	  avidin	  binding.	  Magnetic	  beads	  functionalized	  with	  biotin	  were	  added	  to	  nanoparticle	  solutions	  at	  a	  concentration	  of	  ~10	  binding	  sites	  per	  particle.	  Samples	  were	  collected	  over	  a	  magnet	  for	  at	  least	  24	  hours	  before	  absorbance	  of	  supernatants	  was	  measured	  on	  a	  Cary	  500	  UV-­‐visible	  spectrometer.	  The	  blue	  line	  is	  for	  avidin/C&B-­‐PEG	  coated	  AuNPs,	  the	  green	  and	  read	  spectra	  are	  for	  controls	  of	  C-­‐PEG/B-­‐PEG	  AuNPs	  and	  avidin/C&B-­‐PEG	  coated	  AuNPs	  “blocked”	  with	  free	  avidin,	  respectively.	  	   The	  dramatic	  loss	  of	  the	  characteristic	  gold	  nanoparticle	  peak	  at	  ~520	  nm	  is	  only	  evident	  in	  the	  avidin	  AuNP	  spectrum,	  indicating	  that	  these	  particles	  were	  removed	  from	  solution	  with	  the	  magnetic	  beads.	  In	  order	  to	  remove	  the	  avidin	  AuNPs	  from	  solution,	  they	  must	  have	  bound	  to	  the	  biotin	  present	  on	  the	  magnetic	  beads,	  clearly	  demonstrating	  the	  binding	  ability	  of	  immobilized	  avidin.	  We	  can	  be	  confident	  that	  this	  is	  specifically	  a	  biotin-­‐avidin	  interaction	  because	  the	  “blocked”	  control	  did	  not	  show	  similar	  results.	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Protein	  Modification	  Kit.	  This	  kit	  used	  a	  biotin	  linker	  to	  target	  lysines	  nonspecifically	  in	  the	  protein	  of	  interest,	  in	  this	  case	  As33.	  Dot-­‐blots	  of	  antibodies	  modified	  indicated	  that	  biotinylation	  was	  successful	  (Figure	  A-­‐1,	  Appendix).	  However,	  conjugation	  to	  avidin	  functionalized	  AuNPs	  proved	  to	  be	  a	  more	  complex	  scenario.	  Repeated	  dot-­‐blots	  of	  samples	  of	  biotinylated-­‐As33	  exposed	  avidin	  AuNPs	  yielded	  complete	  lack	  of	  As33	  signal	  (Figure	  10).	  	  
	  
Figure	  10:	  As33	  dot-­‐blots	  on	  As33	  exposed	  avidin	  AuNPs.	  	  300	  ng	  of	  As33	  was	  exposed	  to	  avidin	  AuNPs,	  purified,	  and	  spotted,	  compared	  to	  300	  ng	  of	  unconjugated	  As33	  and	  bare	  nanoparticles.	  	  When	  incubated	  in	  anti-­‐human	  HRP	  conjugated	  secondary	  antibody,	  only	  unconjugated	  As33	  (far	  left)	  was	  detected	  in	  chemiluminescent	  development.	  	   The	  results	  of	  the	  two	  sets	  of	  dot-­‐blots,	  one	  for	  biotin	  and	  one	  of	  the	  presence	  of	  As33	  on	  avidin	  AuNPs,	  indicated	  that	  although	  biotin	  was	  present	  on	  the	  antibodies,	  the	  antibodies	  themselves	  were	  either	  unable	  to	  bind	  to	  avidin	  AuNPs	  or	  unable	  to	  react	  with	  the	  secondary	  antibodies	  used	  in	  these	  blots.	  As	  seen	  in	  Figure	  10,	  modified	  As33	  was	  still	  detectable	  after	  modification,	  but	  not	  after	  conjugation.	  The	  juxtaposition	  of	  these	  assays	  indicated	  that	  the	  biotinylation	  method	  may	  be	  causing	  complications	  in	  antibody-­‐particle	  conjugation.	  Although	  this	  kit	  is	  a	  popular	  protein	  modification	  kit,	  it	  possesses	  some	  drawbacks	  for	  the	  modification	  of	  our	  antibody	  in	  this	  case.	  The	  Chromalink™	  kit	  reacts	  with	  amines	  to	  label	  lysines.	  As	  a	  subclass	  of	  proteins,	  antibodies	  are	  rich	  in	  lysines.	  However,	  lysine	  modification	  may	  also	  cause	  instability	  or	  aggregation	  in	  modified	  antibodies.36	  In	  addition,	  this	  use	  of	  lysines	  can	  be	  problematic	  in	  other	  ways;	  antibodies	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have	  two	  major	  structural	  sections,	  the	  Fc	  and	  Fab	  regions.	  The	  Fc	  region	  is	  the	  “constant”	  region,	  the	  backbone	  of	  the	  antibody,	  whereas	  the	  Fab	  region	  is	  the	  binding	  region.	  If	  biotins	  were	  added	  to	  the	  Fab	  region,	  they	  may	  have	  interfered	  with	  the	  ability	  of	  the	  antibody	  to	  bind	  glycoprotein	  A33	  or	  other	  antibodies,	  for	  example	  during	  a	  dot	  blot.	  This	  would	  make	  the	  antibody	  afunctional.	  In	  fact,	  that	  was	  what	  appeared	  to	  be	  happening	  when	  the	  Chromalink	  kit	  was	  used	  for	  modification.	  Although	  dot	  blots	  that	  detect	  biotin	  were	  positive	  for	  these	  antibodies,	  there	  were	  no	  positive	  results	  when	  these	  antibodies	  were	  conjugated	  to	  AuNPs.	  This	  result	  may	  have	  arisen	  for	  a	  few	  reasons,	  including	  poor	  orientation	  due	  to	  biotin	  modification	  along	  the	  sides	  or	  Fab	  region	  of	  the	  antibody.	  This	  method	  was	  clearly	  not	  successful	  for	  antibody	  modification.	  	   As	  an	  alternative	  to	  the	  Chromalink™	  kit,	  another	  antibody	  modification	  scheme	  was	  prepared.	  Rather	  than	  naturally	  occurring	  handles	  such	  as	  lysines,	  some	  literature	  precedent	  exists	  for	  modifying	  antibodies	  to	  form	  electrophilic	  sites,	  such	  as	  carbonyls,	  to	  develop	  more	  stable	  and	  reliable	  antibody	  conjugates.36	  The	  method	  used	  in	  this	  work,	  developed	  by	  Kumar,37	  oxidizes	  glycosyl	  hydroxyl	  groups	  on	  the	  Fc	  region	  of	  As33	  to	  aldehydes	  through	  meta-­‐periodate	  reactions.37	  From	  there,	  these	  aldehydes	  are	  reacted	  with	  hydrazine-­‐terminated	  linkers	  through	  a	  Wolff-­‐Kischner	  reaction,	  illustrated	  schematically	  in	  Figure	  11,	  which	  forms	  a	  covalent	  bond	  between	  the	  antibody	  and	  the	  linker.	  This	  method	  selectively	  modifies	  the	  Fc	  region,	  controlling	  the	  orientation	  of	  binding	  to	  avidin	  so	  that	  the	  Fab	  region	  will	  be	  facing	  outward	  and	  be	  clear	  to	  bind	  glycoprotein	  A33.	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Figure	  11:	  Wolff-­‐Kischner	  Reaction	  to	  biotinylate	  As33.	  Upon	  the	  conversion	  of	  terminal	  hydroxyl	  groups	  to	  aldehydes,	  hydrazine-­‐terminated	  linkers	  (biotinylated	  linker	  shown)	  were	  reacted	  in	  a	  Wolff-­‐Kischner	  reaction,	  shown	  above.	  Image	  is	  not	  to	  scale,	  but	  is	  simply	  a	  representation	  of	  the	  reaction	  mechanism	  used	  to	  covalently	  bond	  linkers	  to	  antibodies.	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   This	  method	  used	  two	  separate	  linkers,	  one	  with	  a	  thiolated	  terminus	  and	  one	  with	  a	  biotin	  terminus.	  The	  thiolated	  linker	  is	  capable	  of	  binding	  directly	  to	  gold	  surfaces,	  which	  was	  useful	  in	  the	  purposes	  of	  this	  study	  as	  both	  a	  method	  of	  studying	  antibody	  modification	  and	  as	  a	  secondary	  option	  for	  binding.	  The	  addition	  of	  antibodies	  directly	  to	  the	  gold	  surface	  is	  easy	  to	  monitor	  through	  UV-­‐visible	  spectroscopy;	  just	  as	  the	  addition	  of	  PEG	  interacts	  with	  the	  surface	  plasmon	  resonance	  of	  gold	  and	  leads	  to	  a	  red	  shift	  in	  the	  absorbance	  spectrum,	  so	  does	  the	  addition	  of	  an	  antibody.	  Figure	  12	  shows	  a	  normalized	  UV-­‐visible	  spectrum	  for	  bare	  AuNPs	  and	  those	  directly	  functionalized	  with	  As33	  using	  the	  Kumar	  method.	  	  
	  
Figure	  12:	  UV-­‐visible	  spectra	  of	  directly	  conjugated	  nanoparticles.	  The	  addition	  of	  As33	  modified	  with	  a	  thiolated	  PEG	  linker	  to	  the	  surface	  of	  11.2	  nm	  gold	  nanoparticles	  resulted	  in	  a	  5	  nm	  shift	  in	  the	  UV-­‐visible	  spectrum	  Spectra	  acquired	  on	  a	  NanoDrop2000	  (ThermoScientific).	  	   As	  seen	  in	  Figure	  12,	  there	  is	  a	  shift	  from	  519	  nm	  for	  bare	  AuNPs	  to	  approximately	  524	  nm	  for	  antibody	  conjugated	  AuNPs,	  a	  5	  nm	  magnitude	  shift.	  This	  increase	  in	  the	  wavelength	  of	  maximum	  absorbance	  is	  notably	  larger	  than	  the	  shift	  that	  occurs	  with	  the	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addition	  of	  PEG,	  which	  usually	  results	  in	  a	  2	  nm	  magnitude	  red	  shift	  to	  521	  nm	  from	  the	  maximum	  absorbance	  of	  bare	  AuNPs.	  	  In	  this	  case,	  antibody	  conjugation	  could	  be	  clearly	  monitored,	  as	  reported	  in	  Kumar.37	  These	  antibody-­‐conjugated	  AuNPs	  could	  be	  used	  as	  a	  control	  for	  As33	  dot	  blots,	  as	  a	  proof	  that	  AuNPs	  will	  not	  interfere	  with	  the	  chemiluminescent	  dot-­‐blots.	  In	  addition,	  the	  direct	  conjugation	  method	  was	  a	  strong	  secondary	  candidate	  for	  a	  conjugation	  scheme,	  in	  case	  the	  avidin-­‐biotin	  schematic	  continued	  to	  present	  difficulties,	  as	  through	  the	  Chromalink	  kit.	  	   The	  biotinylation	  method	  followed	  the	  same	  reaction	  scheme	  as	  the	  addition	  of	  a	  direct	  linker,	  as	  shown	  in	  Figure	  11.	  However,	  biotinylation	  could	  be	  monitored	  through	  the	  use	  of	  dot-­‐blots.38Dot-­‐blots	  were	  used	  to	  verify	  the	  presence	  of	  biotin	  on	  As33	  before	  conjugation	  to	  avidin-­‐coated	  AuNPs	  was	  attempted.	  	  Figure	  A-­‐3	  (Appendix)	  shows	  the	  use	  of	  a	  biotin-­‐specific	  antibody	  to	  detect	  biotin	  on	  a	  biotin	  standard	  and	  modified	  As33,	  with	  PBS	  as	  a	  negative	  control.	  As	  seen	  in	  Figure	  A-­‐3,	  biotin	  was	  successfully	  detected	  on	  modified	  As33,	  compared	  to	  a	  biotin	  standard	  and	  a	  negative	  control	  (PBS).	  Once	  this	  verification	  had	  taken	  place,	  we	  attempted	  to	  conjugate	  the	  biotinylated-­‐As33	  to	  avidin-­‐coated	  AuNPs.	  	  Following	  this	  conjugation,	  immunoblot	  assays	  were	  again	  performed,	  this	  time	  for	  the	  presence	  of	  As33	  rather	  than	  biotin.	  Dot	  blots	  were	  used	  as	  the	  first	  assay	  for	  the	  presence	  of	  As33	  before	  more	  complex	  assays,	  such	  as	  ELISAs	  and	  DLS,	  were	  used	  to	  further	  characterize	  binding.	  An	  anti-­‐mouse	  antibody	  specific	  to	  As33	  was	  used	  to	  target	  and	  bind	  As33	  on	  the	  surface	  of	  AuNPs,	  and	  the	  HRP	  tag	  on	  this	  antibody	  was	  detected.	  Figure	  13	  shows	  the	  results	  of	  these	  dot-­‐blots,	  wherein	  As33-­‐exposed	  avidin	  AuNPs	  were	  compared	  to	  stock	  solutions	  of	  As33,	  both	  modified	  and	  unmodified,	  and	  to	  PBS,	  which	  acted	  as	  a	  negative	  control.	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Figure	  13:	  Dot	  blots	  probing	  for	  the	  presence	  of	  As33	  on	  AuNPs.	  Dot	  blots	  were	  run	  on	  experimental	  samples	  as	  well	  as	  stock	  solutions	  at	  approximately	  equal	  concentrations,	  which	  acted	  as	  positive	  controls.	  Negative	  controls	  of	  PBS	  and	  avidin	  AuNPs	  were	  performed	  but	  not	  circled	  above.	  As33	  was	  detected	  with	  an	  anti-­‐mouse	  antibody.	  (A)	  Compares	  biotin-­‐avidin	  conjugation	  to	  unmodified,	  unconjugated	  stock	  solutions.	  (B)	  Compares	  stock	  solutions	  of	  As33	  to	  particles	  conjugated	  with	  As33	  directly	  to	  the	  gold	  surface,	  both	  unpurified	  (red)	  and	  purified	  (green	  box).	  Annotation	  by	  Elizabeth	  Durham	  ’16.	  The	  dot	  blots	  shown	  in	  Figure	  13	  demonstrate	  that	  As33	  was	  present	  in	  AuNP	  samples.	  These	  dot-­‐blots	  were	  especially	  valuable	  in	  biotin-­‐avidin	  conjugation	  schemes,	  as	  the	  addition	  of	  antibodies	  could	  not	  be	  visualized	  as	  a	  red	  shift	  in	  UV-­‐visible	  spectra	  in	  this	  case.	  As	  seen	  in	  Figure	  14,	  the	  addition	  of	  biotinylated	  As33	  to	  avidin	  AuNPs	  did	  not	  produce	  a	  significant	  red	  shift	  that	  was	  distinct	  from	  that	  present	  after	  the	  addition	  of	  avidin.	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Figure	  14:	  UV-­‐visible	  spectra	  of	  biotin-­‐avidin	  antibody	  conjugated	  particles.	  Measurements	  were	  taken	  on	  a	  Cary	  500	  UV-­‐visible	  spectrometer	  or	  NanoDrop	  2000	  and	  normalized	  to	  an	  absorbance	  value	  of	  1.0	  to	  ease	  comparison.	  	   Although	  inconvenient,	  the	  result	  of	  this	  spectral	  overlay	  was	  not	  taken	  to	  mean	  that	  As33	  had	  not	  been	  conjugated	  to	  the	  particle.	  Rather,	  the	  position	  of	  the	  As33-­‐exposed	  avidin	  AuNP	  spectrum	  (Figure	  14,	  green	  line)	  over	  the	  avidin	  AuNP	  spectrum	  (Figure	  14,	  blue	  line)	  may	  simply	  imply	  that	  the	  biotin-­‐avidin	  conjugation	  scheme	  resulted	  in	  As33	  tethered	  too	  far	  from	  the	  gold	  surface	  to	  disturb	  further	  the	  surface	  plasmon	  resonance	  of	  the	  AuNPs.	  The	  approximate	  diameter	  of	  avidin	  functionalized	  AuNPs	  is	  38	  nm,	  placing	  biotin	  binding	  sites	  on	  immobilized	  avidin	  nearly	  14	  nm	  from	  the	  gold	  surface.	  It	  is	  not	  unreasonable	  to	  believe	  that	  the	  antibody,	  which	  includes	  a	  PEG	  linker,	  would	  be	  too	  far	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removed	  from	  the	  metallic	  gold	  surface	  to	  disrupt	  the	  behavior	  of	  electrons	  in	  the	  gold	  surface,	  and	  therefore	  not	  able	  to	  cause	  a	  red	  shift	  of	  UV-­‐visible	  spectra.	  	  Following	  the	  success	  of	  dot-­‐blots	  to	  show	  the	  presence	  of	  As33	  in	  As33	  exposed	  avidin	  AuNP	  samples	  (Figure	  13),	  other	  assays	  were	  undertaken	  to	  independently	  confirm	  the	  presence	  of	  As33.	  The	  conjugation	  of	  both	  C-­‐PEG/B-­‐PEG	  and	  avidin	  to	  AuNPs,	  for	  example,	  leads	  to	  size	  changes	  that	  can	  be	  tracked	  using	  DLS.	  	  Therefore,	  it	  was	  also	  expected	  that	  the	  conjugation	  of	  As33,	  which	  is	  considerably	  larger	  than	  avidin	  (Figure	  5),	  would	  also	  yield	  significant	  size	  changes.	  	  Here	  the	  mean	  size	  from	  the	  number	  particle	  size	  distribution	  was	  approximately	  33	  nm,	  but	  also	  included	  readings	  around	  200–300	  nm.	  This	  value	  did	  not	  present	  the	  significant	  increase	  from	  the	  mean	  diameter	  of	  avidin	  AuNPs	  (38	  nm)	  expected.	  However,	  there	  was	  a	  great	  deal	  of	  variability	  in	  these	  samples,	  although	  the	  polydispersion	  index	  was	  typically	  at	  or	  above	  0.4.	  In	  addition,	  presence	  of	  antibodies	  made	  the	  solutions	  impossible	  to	  filter	  without	  significant	  sample	  loss.	  Because	  these	  particles	  could	  not	  be	  filtered,	  dust	  or	  excess	  PEG,	  avidin,	  or	  antibodies	  could	  be	  increasing	  the	  PDI	  and	  contributing	  to	  the	  variability	  within	  the	  samples.	  Either	  way,	  further	  testing	  was	  done	  on	  these	  particles	  to	  quantify	  As33	  conjugation	  to	  the	  surface	  of	  AuNPs.	  	  Enzyme-­‐linked	  immunosorbent	  assays	  were	  harnessed	  for	  the	  purpose	  of	  quantifying	  the	  conjugation	  of	  As33	  to	  AuNPs.	  Standard	  curves	  of	  As33	  from	  1	  μg/mL	  to	  0	  ng/mL	  were	  constructed	  as	  a	  reference	  point	  against	  which	  to	  compare	  experimental	  samples,	  as	  shown	  in	  Figure	  A-­‐4.	  Experimental	  samples	  were	  also	  prepared	  in	  a	  range	  of	  dilutions,	  calculated	  from	  UV-­‐vis	  spectroscopy	  performed	  on	  a	  NanoDrop	  2000	  (ThermoScientific).	  The	  ELISAs	  were	  replicated	  several	  times	  for	  each	  conjugation	  method,	  seen	  in	  Table	  3.	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Table	  3:	  Antibodies	  per	  particle	  calculated	  through	  ELISAs.	  Each	  sample	  was	  compared	  to	  a	  standard	  curve	  of	  As33	  from	  0–1	  μg/mL	  prepared	  at	  the	  same	  time	  as	  experimental	  samples.	  The	  absorbance	  data	  for	  experimental	  samples	  was	  then	  fit	  to	  these	  curves.	  Plates	  were	  read	  on	  a	  Spectra	  Max	  M3	  plate	  reader	  from	  Molecular	  Devices.	  
Sample	   Antibodies	  per	  
AuNP	  
Direct	  Conjugation	  SM2093	   2.4	  ±	  0.8	  SM2093	   5.4	  ±	  1.5	  ED1087	   2.5	  ±	  1.0	  
Biotin-­‐Avidin	  Conjugation	  ED1087	   2.7	  ±	  0.1	  SM3011	   2.1	  ±	  0.2	  SM3033*	   3.5	  ±	  0.5	  	   Direct	  conjugation	  methods	  yielded	  approximately	  3.4	  ±	  1.7	  antibodies	  per	  particle	  on	  average,	  but	  with	  a	  very	  high	  level	  of	  variability	  in	  the	  number	  of	  antibodies	  per	  particle	  from	  sample	  to	  sample.	  This	  wide	  range	  in	  the	  number	  of	  antibodies	  per	  particle	  is	  reflected	  in	  the	  broadness	  of	  the	  UV-­‐vis	  peak	  of	  direct	  conjugation	  (Figure	  12).	  In	  contrast,	  biotin-­‐avidin	  conjugation	  methods	  held	  consistently	  at	  approximately	  2.4	  ±	  0.4	  antibodies	  per	  particle,	  a	  much	  more	  reasonable	  margin	  of	  error.	  One	  sample,	  SM3033,	  denoted	  with	  a	  star	  in	  Table	  3,	  was,	  by	  mistake,	  prepared	  with	  a	  higher	  concentration	  of	  As33	  to	  AuNPs	  than	  prior	  biotin-­‐avidin	  conjugation	  schemes,	  as	  the	  concentration	  of	  avidin	  AuNPs	  in	  solution	  was	  notably	  lower.	  However,	  this	  sample	  indicates	  that	  increasing	  the	  concentration	  of	  antibodies	  in	  solution	  relative	  to	  AuNPs	  increased	  the	  concentration	  of	  antibodies	  per	  particle.	  If	  this	  trend	  holds	  true,	  the	  concentration	  of	  As33	  to	  AuNPs	  through	  biotin-­‐avidin	  conjugation	  could	  be	  increased,	  if	  necessary.	  For	  example,	  if,	  for	  some	  reason,	  cell	  uptake	  trials	  were	  unsuccessful	  once	  the	  particle	  surface	  was	  fully	  functionalized,	  a	  higher	  concentration	  of	  As33	  per	  particle	  may	  solve	  that	  problem.	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   Overall,	  the	  biotin-­‐avidin	  system	  of	  conjugation	  was	  selected	  as	  the	  method	  of	  choice,	  as	  the	  low	  standard	  deviation	  and	  flexibility	  of	  the	  method	  made	  it	  promising.	  It	  is	  highly	  favorable	  to	  keep	  the	  particles	  as	  uniform	  as	  possible	  in	  each	  step	  in	  order	  to	  ensure	  that	  the	  end	  product	  will	  be	  uniform	  and	  stable.	  In	  addition,	  in	  the	  biotin-­‐avidin	  system,	  the	  antibodies	  have	  a	  much	  higher	  clearance	  from	  the	  gold	  surface.	  This	  distance	  will,	  most	  likely,	  diminish	  the	  steric	  hindrance	  of	  the	  As33	  and	  make	  it	  easier	  for	  As33	  to	  bind	  gpA33	  on	  cell	  surfaces,	  which	  is	  absolutely	  essential	  for	  the	  success	  of	  this	  particle	  as	  a	  cancer	  treatment	  vehicle.	  Should	  this	  method	  be	  unsuccessful,	  however,	  there	  are	  beneficial	  aspects	  to	  direct	  conjugation	  to	  keep	  in	  mind;	  for	  instance,	  the	  surface	  could	  be	  loaded	  with	  as	  many	  antibodies	  as	  necessary	  before	  the	  addition	  of	  PEG,	  and	  all	  avidin	  binding	  sites	  would	  be	  open	  to	  polyGL,	  rather	  than	  antibodies.	  Antibodies	  bound	  closer	  to	  the	  surface	  will	  not	  be	  as	  free	  to	  interact	  with	  the	  cell	  surface,	  but	  that	  may	  also	  minimize	  the	  potential	  for	  these	  antibodies	  to	  trigger	  an	  immune	  reaction.	  Either	  way,	  these	  results	  indicate	  promising	  avenues	  for	  antibody	  conjugation.	  
PolyGL	  Modification	  and	  Conjugation	  	   To	  complete	  the	  surface	  functionalization	  of	  gold	  nanoparticles	  for	  the	  purpose	  of	  targeting	  and	  treating	  pancreatic	  cancer,	  the	  therapeutic	  agent	  needs	  to	  be	  in	  place.	  In	  this	  project	  we	  seek	  to	  revive	  boron	  neutron	  capture	  therapy	  (BNCT)	  through	  a	  heavily	  boronated	  peptide	  made	  of	  repeating	  D-­‐lysine	  and	  D-­‐glutamate	  residues	  in	  a	  6:4	  glutamate:	  lysine	  ratio,	  hereafter	  referred	  to	  as	  polyGL.	  BNCT	  is	  an	  attractive	  area	  of	  research	  as	  a	  method	  of	  cancer	  treatment	  because	  of	  the	  adaptability	  of	  the	  system.	  Although	  free	  boron	  was	  a	  failure	  in	  BNCT,	  because	  it	  yields	  widespread	  damage,	  nanotherapeutics	  can	  bring	  dosages	  of	  boron	  to	  cancerous	  tissue	  specifically.	  Because	  nanoparticles	  travel	  throughout	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the	  blood	  stream,	  metastatic	  tumors	  could	  be	  treated	  with	  BNCT	  through	  nanoscience,	  greatly	  expanding	  the	  survival	  rate	  of	  cancer	  patients	  everywhere.39	  Some	  boron-­‐loaded	  particles	  have	  already	  been	  developed	  for	  use	  within	  mammalian	  systems.40,41	  	  	   The	  particles	  in	  development	  in	  this	  work	  would	  be	  loaded	  with	  boron	  through	  modified	  peptides,	  which	  are	  in	  turn	  conjugated	  through	  biotin-­‐avidin	  binding.	  Boron	  conjugation	  was	  not	  undertaken	  as	  part	  of	  this	  thesis,	  but	  work	  was	  done	  on	  modifying	  and	  conjugating	  the	  peptide,	  polyGL.	  For	  conjugation,	  polyGL	  needs	  to	  be	  biotinylated,	  but	  the	  Wolff-­‐Kischner	  reaction	  used	  for	  antibody	  modification	  was	  not	  adapted	  to	  modifying	  the	  peptide.	  The	  structure	  of	  polyGL	  is	  flexible	  enough	  that	  the	  addition	  of	  a	  long	  PEG	  linker	  to	  the	  biotin	  is	  unnecessary.	  In	  addition,	  it	  is	  a	  very	  large	  polymer,	  and	  the	  addition	  of	  excess	  bulk	  in	  the	  form	  of	  a	  PEG	  linker	  would	  only	  make	  the	  particle	  more	  massive	  when	  it	  was	  conjugated.	  Furthermore,	  a	  protocol	  for	  the	  biotinylation	  of	  polyGL	  had	  been	  established	  by	  collaborator	  Sara	  Althari	  as	  part	  of	  her	  thesis	  work.33	  As	  stated	  when	  considering	  the	  benefits	  of	  the	  Chromalink™	  Protein	  Modification	  Kit,	  primary	  amines	  are	  a	  common	  modification	  target,	  and	  fortunately	  polyGL	  is	  rich	  in	  lysines.	  In	  contrast	  with	  As33,	  however,	  modifying	  lysines	  on	  polyGL	  will	  not	  interfere	  with	  function.	  PolyGL	  is	  an	  unstructured	  peptide	  that	  simply	  acts	  as	  a	  carrier;	  the	  presence	  of	  a	  biotin	  moiety	  within	  the	  center	  of	  the	  peptide	  will	  be	  no	  more	  or	  less	  disruptive	  than	  a	  terminally	  bound	  biotin.	  In	  fact,	  the	  flexible	  nature	  of	  a	  simple	  peptide	  means	  that	  terminal	  biotinylation	  is	  also	  not	  a	  pressing	  concern	  for	  this	  system.	  With	  this	  in	  mind,	  biotin	  was	  conjugated	  to	  polyGL	  by	  reacting	  primary	  amines	  with	  sulfo-­‐NHS-­‐biotin,	  a	  reaction	  that	  covalently	  bonds	  biotin	  directly	  to	  lysine	  residues,	  without	  an	  additional	  linker.	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   Using	  this	  reaction,	  as	  optimized	  by	  Sara	  Althari	  ’13,33	  polyGL	  was	  biotinylated	  and	  this	  biotinylation	  was	  assessed	  through	  dot	  blots,	  as	  it	  was	  for	  As33.	  These	  dot	  blots,	  as	  shown	  in	  Figure	  A-­‐2	  (Appendix),	  compared	  biotinylated	  polyGL	  to	  biotin	  standards	  and	  PBS	  in	  the	  presence	  of	  a	  biotin-­‐specific,	  HRP-­‐conjugated	  antibody.	  These	  assessments	  were	  positive,	  but	  it	  was	  useful	  for	  the	  purposes	  of	  this	  project	  to	  quantify	  the	  amount	  of	  biotin	  per	  molecule	  of	  polyGL,	  to	  ensure	  that	  there	  is	  at	  least	  one	  biotin	  molecule	  per	  peptide,	  as	  dot	  blots	  are	  unable	  to	  ascertain	  concentrations.	  In	  addition,	  on	  a	  large	  molecule	  such	  as	  polyGL,	  it	  might	  be	  beneficial	  to	  have	  more	  than	  one	  biotin	  per	  molecule,	  to	  increase	  chances	  of	  binding.	  To	  this	  end,	  the	  Quant*Tag	  kit	  was	  used	  to	  measure	  the	  amount	  of	  biotin	  in	  solutions	  of	  polyGL.	  A	  colorimetric	  standard	  curve	  of	  0–10	  nmol/mL	  biotin,	  as	  presented	  in	  Figure	  A-­‐4	  (Appendix),	  was	  used	  as	  a	  reference	  for	  the	  concentration	  of	  biotin	  in	  polyGL	  solutions.	  The	  results	  of	  this	  assay,	  across	  several	  samples,	  are	  reported	  in	  Table	  4.	  	  
Table	  4:	  Quant*Tag	  absorbance	  results.	  The	  absorbance	  at	  535	  nm	  of	  biotinylated	  polyGL	  samples	  was	  translated	  to	  the	  number	  of	  biotin	  moieties	  per	  polyGL	  using	  a	  standard	  curve	  generated	  from	  biotin	  standards.	  Measurements	  were	  taken	  on	  a	  Spectra	  Max	  M3	  plate	  reader	  from	  Molecular	  Devices.	  




SM2096	   0.33	   7.3	  
SM3005	  #1	   0.06	   9.8	  
SM3005	  #2	  	   0.05	   3.3	  	   Using	  the	  Quant*Tag	  assay,	  I	  found	  that	  there	  was	  some	  variation	  among	  samples	  of	  polyGL,	  with	  anywhere	  from	  3–9	  biotin	  molecules	  per	  polyGL,	  on	  average,	  across	  functionalization	  batches.	  The	  established	  procedure	  called	  for	  a	  molar	  ratio	  of	  5:1	  biotin	  to	  peptide,33	  but	  this	  ratio	  was	  exceeded	  for	  this	  project.	  However,	  if,	  in	  the	  future,	  the	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number	  of	  biotins	  per	  particle	  needs	  to	  be	  decreased,	  we	  know	  that	  such	  a	  ratio	  has	  been	  performed	  successfully.	  	   After	  thorough	  assessment	  of	  the	  biotinylation	  of	  polyGL,	  the	  first	  attempts	  were	  made	  to	  conjugate	  polyGL	  to	  avidin-­‐functionalized	  AuNPs.	  In	  order	  to	  determine	  the	  success	  of	  the	  addition	  of	  polyGL	  to	  avidin	  AuNPs,	  DLS	  and	  Zeta-­‐potential	  measurements	  were	  conducted.	  PolyGL	  is	  a	  massive	  peptide,	  which	  would	  likely	  produce	  a	  large	  size	  change,	  measurable	  by	  DLS.	  The	  results	  of	  DLS	  measurements	  of	  polyGL	  conjugated	  AuNPs	  are	  presented	  in	  Figure	  15.	  Here	  we	  see	  that	  the	  diameter	  increases	  about	  18	  nm	  with	  the	  addition	  of	  C-­‐PEG/B-­‐PEG,	  and	  that	  the	  size	  distribution	  widens	  to	  include	  some	  larger	  particles	  with	  the	  addition	  of	  avidin,	  but	  that	  there	  was	  no	  significant	  size	  increase	  following	  the	  conjugation	  of	  polyGL.	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Figure	  15:	  Dynamic	  light	  scattering	  of	  particles	  functionalized	  with	  C-­‐PEG/B-­‐PEG,	  avidin,	  and	  polyGL	  
compared	  to	  bare	  AuNPs.	  The	  diameter	  of	  AuNPs	  often	  shows	  clear	  shifts	  upon	  functionalization,	  as	  with	  the	  addition	  of	  C-­‐PEG/B-­‐PEG	  (red	  line)	  from	  bare	  AuNPs	  (black	  line).	  Unfortunately,	  similar	  shifts	  were	  more	  difficult	  to	  determine	  in	  the	  presence	  of	  avidin	  (blue	  line)	  and	  polyGL	  (green	  line)	  in	  DLS	  data.	  Measurements	  were	  taken	  on	  a	  ZetaSizer	  Nano	  2000,	  by	  Malvern	  Instruments.	  	   Unfortunately,	  DLS	  data	  from	  after	  polyGL	  addition	  did	  not	  show	  any	  shift	  in	  the	  diameter	  of	  the	  particles,	  although	  there	  was	  a	  noticeable	  increase	  in	  the	  polydispersion	  index	  (PDI).	  This	  increase	  in	  PDI	  indicates	  that	  the	  size	  of	  nanoparticles	  within	  the	  solution	  became	  much	  less	  uniform.	  The	  exact	  size	  change	  produced	  by	  adding	  polyGL	  was	  difficult	  to	  predict,	  as	  the	  behavior	  of	  polyGL	  in	  solution	  had	  not	  been	  characterized.	  If	  the	  biotin	  that	  bound	  avidin	  was	  at	  the	  peptide	  terminus,	  two	  things	  could	  happen;	  the	  polyGL	  could	  extend	  in	  solution,	  making	  a	  large	  contribution	  to	  the	  particle	  diameter,	  or	  it	  could	  curl	  up	  upon	  itself,	  through	  electrostatic	  interactions,	  greatly	  minimizing	  size	  shifts.	  If,	  on	  the	  other	  hand,	  conjugation	  to	  avidin	  occurred	  through	  a	  biotin	  moiety	  on	  a	  central	  lysine,	  the	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contribution	  to	  diameter	  would	  be	  substantially	  less	  than	  that	  of	  a	  terminally-­‐bound	  biotin	  moiety.	  In	  addition,	  a	  second	  peak	  appeared	  around	  200–300	  nm,	  although	  this	  was	  much	  too	  large	  to	  correspond	  to	  polyGL	  functionalized	  particles.	  As	  such,	  DLS	  was	  inconclusive	  for	  the	  addition	  of	  polyGL,	  and	  other	  methods	  needed	  to	  be	  examined.	  	   Zeta-­‐Potential	  measurements,	  which	  track	  shifts	  in	  the	  overall	  charge	  of	  particles	  post-­‐functionalization,	  were	  also	  explored	  to	  confirm	  polyGL	  attachment	  to	  the	  particles.	  The	  complexity	  of	  zeta-­‐potential	  measurements	  with	  nanoparticles	  is	  complicated	  by	  the	  presence	  of	  even	  a	  single	  ligand	  layer42;	  the	  data	  from	  Zeta-­‐Potential	  often	  came	  in	  the	  form	  of	  two	  to	  three	  separate	  peaks	  of	  varying	  strength	  and	  position,	  but	  some	  of	  the	  cleanest	  readings	  put	  avidin	  AuNPs	  at	  –50.2	  ±	  15.3	  mV	  and	  polyGL	  AuNPs	  at	  -­‐46.5	  ±	  19.9	  mV.	  Not	  surprisingly,	  a	  Student’s	  t-­‐test	  on	  this	  data	  demonstrates	  that	  there	  is	  no	  significant	  difference	  between	  the	  two	  means	  at	  the	  95%	  confidence	  level.	  As	  polyGL	  is	  a	  highly	  charged	  peptide,	  with	  six	  glutamates	  for	  every	  four	  lysines,	  the	  addition	  of	  polyGL	  should	  shift	  the	  overall	  charge	  of	  the	  particle,	  measured	  by	  Zeta-­‐Potential,	  to	  an	  even	  more	  negative	  value.	  	  In	  addition,	  biotin	  moieties	  bound	  to	  lysine	  residues,	  further	  increasing	  the	  disparity	  of	  charge	  in	  favor	  of	  glutamate.	  However,	  there	  were	  some	  challenges	  to	  using	  Zeta-­‐Potential	  for	  this	  system;	  namely,	  the	  complexity	  of	  the	  particle	  led	  to	  variable	  charges	  within	  and	  between	  particles,	  driving	  up	  standard	  deviations	  for	  charge	  measurements	  and	  driving	  down	  accuracy.	  The	  Zeta-­‐potential	  of	  nanoparticles	  is	  notoriously	  difficult	  to	  appropriately	  measure	  and	  interpret.42	  Therefore,	  the	  use	  of	  Zeta-­‐Potential	  was	  just	  as	  inconclusive	  for	  the	  presence	  of	  polyGL	  as	  DLS	  was,	  and	  additional	  assays	  needed	  to	  be	  developed.	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   To	  this	  end,	  gel	  electrophoresis	  was	  introduced	  as	  a	  method	  to	  assess	  changes	  in	  the	  overall	  mass	  and	  charge	  of	  the	  particles	  and	  track	  shifts	  throughout	  the	  synthesis	  process.	  Although	  inexact	  for	  complex	  particles,	  Zeta-­‐Potential	  clearly	  demonstrates	  that	  bare,	  PEG,	  avidin,	  and	  polyGL	  AuNPs	  were	  all	  predominantly	  negative,	  although	  there	  were	  some	  shifts	  in	  the	  magnitude	  of	  the	  negative	  charge	  as	  additional	  layers	  were	  added.	  This	  method	  has	  successfully	  been	  used	  for	  the	  evaluation	  of	  the	  conjugation	  of	  polymers	  and	  peptides	  to	  gold	  nanoparticles.34,43	  Researchers	  were	  even	  able	  to	  see	  differences	  in	  distance	  traveled	  from	  the	  ratio	  of	  PEG	  per	  particle,	  for	  instance.34	  For	  the	  purposes	  of	  this	  study,	  gels	  were	  run	  on	  particles	  at	  all	  stages	  of	  functionalization,	  from	  bare	  AuNPs	  to	  polyGL	  conjugated	  AuNPs,	  as	  shown	  in	  Figure	  16.	  
	  
Figure	  16:	  Gel	  electrophoresis	  of	  functionalized	  AuNPs.	  Gel	  electrophoresis	  of	  samples	  of	  AuNPs	  (OD	  ~	  14)	  at	  varying	  stages	  of	  functionalization.	  The	  concentration	  of	  avidin	  AuNPs	  was	  lower	  than	  the	  other	  samples;	  for	  convenience,	  the	  band	  is	  boxed	  in	  this	  image.	  Gels	  were	  run	  for	  1	  hour	  at	  80	  V.	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This	  assay	  was	  performed	  with	  particles	  at	  varying	  stages	  of	  functionalization	  acting	  as	  controls,	  to	  show	  that	  mass	  and	  charge	  shifts	  would	  be	  apparent	  in	  the	  gel.	  As	  seen	  in	  Figure	  16,	  nanoparticles	  conjugated	  with	  polyGL	  through	  avidin	  moves	  further	  through	  the	  gel	  than	  avidin	  AuNPs,	  despite	  a	  larger	  mass.	  Because	  charges	  were	  not	  equal	  in	  all	  samples,	  the	  distance	  traveled	  depended	  on	  both	  the	  charge	  and	  the	  mass	  of	  the	  particles	  in	  question.	  For	  example,	  two	  AuNP	  samples	  were	  prepared	  for	  this	  assay,	  one	  with	  fully	  charged	  native	  avidin	  and	  one	  with	  Neutravidin,	  an	  avidin	  product	  wherein	  charges	  were	  neutralized.	  These	  particles	  had	  the	  same	  mass,	  but	  Neutravidin	  particles	  did	  not	  move	  as	  far	  through	  the	  gel,	  as	  they	  possessed	  less	  charge	  and	  were,	  therefore,	  less	  attracted	  to	  the	  positive	  electrode.	  Making	  predictions	  for	  the	  difference	  between	  polyGL	  AuNPs	  and	  avidin	  AuNPs	  was	  a	  little	  more	  complicated,	  as	  polyGL	  AuNPs	  would	  be	  more	  massive	  if	  conjugation	  was	  successful,	  but	  they	  would	  also	  be	  more	  negatively	  charged.	  The	  difference	  in	  charge	  was	  likely	  to	  be	  the	  greater	  factor,	  however,	  as	  each	  particle	  only	  had	  between	  3-­‐5	  avidins	  per	  particle.	  	  Therefore,	  there	  could	  be	  at	  most	  15	  polyGL	  peptides	  bound	  to	  each	  avidin	  AuNP,	  each	  contributing	  two	  net	  negative	  charges	  and	  decreasing	  the	  overall	  charge	  of	  the	  particle.	  	  	  In	  fact,	  the	  band	  position	  of	  polyGL	  exposed	  avidin	  AuNPs	  ends	  up	  directly	  between	  avidin	  AuNPs	  and	  bare	  particles	  that	  were	  functionalized	  only	  with	  polyGL	  peptides,	  without	  PEG	  or	  avidin,	  which	  more	  cleanly	  shows	  the	  effect	  of	  charge	  in	  the	  presence	  of	  gold	  nanoparticles.	  These	  results	  are	  indicative	  of	  successful	  addition	  of	  polyGL	  to	  avidin	  AuNPs,	  as	  there	  was	  a	  clear	  shift	  in	  band	  position,	  which	  would	  not	  have	  occurred	  without	  meaningful	  changes	  to	  particle	  charge	  and	  mass.	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   Although	  the	  results	  from	  gel	  electrophoresis	  were	  promising,	  the	  technique	  is	  not	  quantitative.	  Therefore,	  an	  important	  next	  step	  in	  particle	  assessment	  was	  a	  secondary	  assay	  to	  show	  that	  polyGL	  was	  bound,	  and	  quantify	  the	  ratio	  of	  polyGL	  peptides	  per	  particle.	  A	  fluorescence-­‐based	  assay	  for	  the	  presence	  of	  amines,	  the	  CBQCA	  assay,	  became	  the	  method	  of	  choice.	  A	  specially	  prepared	  fluorophore,	  shown	  in	  Figure	  17,	  binds	  to	  amine	  groups,	  like	  the	  ones	  found	  in	  lysine	  in	  polyGL.	  Upon	  binding,	  a	  fluorescent	  signal	  is	  produced,	  which	  was	  measured	  using	  fluorescence	  settings	  on	  a	  Spectra	  Max	  M3	  (Molecular	  Devices)	  plate	  reader	  and	  contextualized	  with	  the	  use	  of	  a	  standard	  curve.	  However,	  this	  assay	  may	  have	  problems	  when	  used	  in	  the	  presence	  of	  gold	  nanoparticles,	  and	  so	  care	  had	  to	  be	  taken	  to	  study	  the	  behavior	  of	  gold	  nanoparticles	  and	  the	  various	  proteins	  of	  interest	  in	  the	  presence	  of	  this	  fluorophore.	  
	  
Figure	  17:	  Structure	  of	  the	  CBQCA	  fluorophore.	  The	  most	  pressing	  concern	  was	  the	  fact	  that	  gold	  is	  a	  well-­‐characterized	  fluorescence	  quencher.4,5	  Fluorescence	  quenching	  is	  the	  phenomenon	  wherein	  a	  molecule	  that	  typically	  releases	  excess	  energy	  as	  light	  in	  a	  fluorescent	  signal	  is	  in	  close	  proximity	  to	  a	  second	  molecule,	  the	  “quencher,”	  that	  is	  capable	  of	  absorbing	  that	  energy	  from	  the	  excited	  state	  fluorophore,	  and	  does	  not	  produce	  its	  own	  fluorescent	  emission.4	  Gold	  is	  such	  a	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strong	  fluorescence	  quencher,	  in	  fact,	  that	  gold	  nanoparticles	  have	  been	  used	  for	  biosensors	  to	  study	  interactions	  and	  for	  FRET-­‐like	  assays.4,5	  It	  was	  entirely	  possible,	  therefore,	  that	  this	  assay	  would	  have	  provided	  no	  useable	  data,	  as	  any	  fluorescent	  signal	  would	  have	  been	  extinguished	  by	  the	  presence	  of	  gold.	  	  In	  addition,	  the	  kit	  itself	  warned	  of	  the	  potential	  for	  thiols	  to	  negatively	  impact	  fluorescent	  signal.	  This	  was	  an	  issue	  because	  the	  conjugation	  of	  PEG	  to	  the	  gold	  surface	  is	  the	  product	  of	  a	  thiol	  bond,	  and	  a	  single	  avidin	  dimer	  has	  24	  cysteines,	  amino	  acids	  with	  thiol	  groups	  on	  their	  side-­‐chains.	  For	  this	  reason,	  this	  assay	  was	  first	  performed	  under	  eight	  separate	  control	  conditions,	  to	  assess	  the	  changes	  in	  fluorescent	  signal	  when	  in	  the	  presence	  of	  AuNPs	  (Figure	  A-­‐5).	  For	  example,	  standard	  curves	  of	  unbound	  polyGL	  were	  run	  with	  and	  without	  the	  presence	  of	  M-­‐PEG	  (methoxy-­‐PEG-­‐thiol)	  AuNPs,	  to	  see	  if	  there	  was	  a	  significant	  decrease	  in	  fluorescent	  signal	  and	  whether	  the	  curves	  remained	  linear.	  Although	  these	  assessments	  indicated	  that	  the	  presence	  of	  AuNPs	  did,	  in	  fact,	  attenuate	  fluorescence,	  it	  did	  so	  in	  a	  predictable	  manner,	  and	  the	  standard	  curves	  remained	  linear.	  These	  findings	  were	  taken	  into	  account	  when	  running	  experimental	  samples.	  When	  attempting	  to	  quantify	  both	  avidin	  and	  polyGL	  on	  the	  surface	  of	  gold	  nanoparticles,	  standard	  curves	  of	  avidin	  and	  polyGL	  from	  0–1000	  ng	  were	  prepared,	  but	  PEG	  AuNPs	  were	  added	  to	  each	  well	  at	  the	  same	  gold	  concentration	  as	  AuNP	  experimental	  samples;	  these	  concentrations	  were	  set	  using	  the	  peak	  absorbance	  at	  522	  nm	  found	  on	  a	  NanoDrop	  2000.	  By	  keeping	  the	  concentration	  of	  AuNPs	  constant	  in	  both	  controls	  and	  experimental	  samples,	  the	  effects	  of	  gold	  and	  thiols	  should	  have	  been	  the	  same	  in	  all	  wells,	  so	  they	  could	  be	  ignored	  when	  analyzing	  the	  data.	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With	  the	  set-­‐up	  described	  above,	  the	  number	  of	  avidins	  per	  particle	  was	  calculated	  to	  be	  approximately	  2.5.	  This	  value	  falls	  within	  a	  reasonable	  range,	  as	  most	  avidin	  AuNP	  samples	  were	  set	  up	  to	  have	  anywhere	  from	  3–5	  avidins	  per	  particle,	  assuming	  every	  avidin	  in	  solution	  bound	  a	  particle.	  In	  addition,	  this	  value	  approximately	  matched	  the	  number	  of	  antibodies	  per	  avidin	  particle	  found	  in	  ELISAs,	  which	  should	  match	  closely	  if	  As33	  is	  binding	  to	  avidin.	  This	  agreement	  between	  methods	  was	  a	  good	  indication	  that	  this	  assay	  could	  accurately	  predict	  the	  amount	  of	  protein	  in	  solution,	  even	  in	  the	  presence	  of	  gold.	  Fluorescence	  measurements	  found	  in	  this	  assay	  are	  shown	  in	  Table	  5,	  and	  were	  fit	  to	  standard	  curves	  shown	  in	  Figures	  A-­‐7	  and	  A-­‐8	  (Appendix).	  
Table	  5:	  CBQCA	  assay	  data	  from	  avidin	  AuNP	  and	  polyGL	  AuNP	  samples.	  Samples	  were	  incubated	  with	  the	  CBQCA	  fluorophore	  for	  one	  hour.	  Fluorescence	  emission	  measurements	  were	  made	  with	  a	  Spectra	  Max	  M3	  plate	  reader	  from	  Molecular	  Devices.	  





535	  nm	  Sample	  1	   27.4	   102.7	  Sample	  2	   18.4	   121.9	  Sample	  3	   17.9	   112.9	  
Average	   21.2	   112.5	  	  The	  true	  utility	  of	  the	  CBQCA	  kit	  is	  that	  it	  enables	  us	  to	  determine	  the	  number	  of	  polyGL	  peptides	  per	  AuNP.	  The	  total	  fluorescent	  signal	  from	  polyGL	  AuNP	  samples	  clearly	  showed	  that	  there	  were	  more	  amines	  in	  solution	  than	  in	  the	  avidin	  AuNP	  samples,	  indicating	  that	  polyGL	  was	  present	  in	  these	  samples.	  However,	  when	  converting	  this	  raw	  fluorescent	  signal	  to	  the	  number	  of	  polyGL	  peptides	  per	  particle,	  this	  assay	  predicted	  approximately	  77	  peptides	  were	  bound	  to	  each	  AuNP	  on	  average.	  For	  accuracy,	  the	  raw	  signal	  from	  the	  avidin	  samples	  were	  subtracted	  from	  polyGL	  samples,	  to	  account	  for	  the	  presence	  of	  avidin	  on	  these	  particles	  as	  well.	  Obviously,	  particles	  cannot	  accommodate	  77	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polyGL	  peptides	  through	  biotin-­‐avidin	  interactions	  because	  there	  are	  only	  2.5	  avidins	  per	  particle.	  Therefore,	  with	  this	  avidin	  loading,	  the	  most	  a	  particle	  could	  bind	  would	  be	  7.5	  peptides,	  as	  each	  avidin	  has	  three	  biotin-­‐binding	  sites	  open	  after	  binding	  biotin-­‐PEG.	  There	  are	  some	  possible	  sources	  for	  this	  assay	  significantly	  overestimating	  the	  number	  of	  polyGL	  peptides	  per	  particle,	  however.	  One	  possibility	  is	  that	  repeated	  rounds	  of	  purification	  the	  polyGL	  AuNPs	  underwent	  were	  not	  sufficient	  to	  completely	  remove	  all	  excess	  polyGL	  from	  solution.	  The	  presence	  of	  excess	  polyGL	  in	  solution	  would	  increase	  the	  signal	  observed	  in	  the	  CBQCA	  assay.	  	  A	  second	  possibility	  lies	  in	  the	  behavior	  of	  these	  peptides	  in	  solution.	  Unbound	  polyGL,	  floating	  free	  in	  solution,	  is	  full	  of	  the	  potential	  for	  internal	  electrostatic	  interactions,	  and	  so	  may	  coil	  in	  upon	  itself,	  effectively	  shielding	  many	  amines	  from	  solution,	  and	  therefore	  from	  the	  peptide.	  In	  contrast,	  when	  bound	  to	  avidin	  AuNPs	  through	  biotin	  moieties,	  which	  are	  scattered	  throughout	  the	  polymer,	  the	  peptide	  may	  be	  forced	  into	  a	  more	  open	  conformation,	  imparting	  greater	  accessibility	  of	  the	  fluorophore	  to	  the	  lysine	  residues	  in	  the	  polyGL.	  This	  conformational	  change	  in	  polymers	  is	  commonly	  found	  in	  PEG	  when	  it	  binds	  to	  gold	  surfaces.34,42	  Depending	  on	  the	  extent	  of	  the	  difference	  between	  bound	  and	  unbound	  states,	  this	  may	  be	  a	  major	  player	  in	  the	  difference	  in	  signal	  intensity.	  	  However,	  it	  is	  unlikely	  that	  either	  of	  these	  would	  have	  increased	  the	  polyGL	  signal	  ten-­‐fold	  higher	  than	  it	  should	  have	  been.	  Another	  consideration	  should	  be	  taken	  into	  account	  while	  evaluating	  the	  difference	  in	  this	  data,	  which	  is	  that	  polyGL	  is	  capable	  of	  binding	  gold	  directly,	  through	  amine	  bonds	  with	  the	  gold	  surface.	  Samples	  in	  this	  work	  have	  been	  prepared	  with	  polyGL	  bound	  directly	  to	  the	  gold	  surface,	  demonstrating	  the	  ease	  through	  which	  this	  occurs.	  It	  is	  possible,	  therefore,	  that	  the	  increase	  in	  polyGL	  signal	  seen	  in	  the	  CBQCA	  assay	  could	  be	  because	  polyGL	  is	  displacing	  some	  C-­‐PEG	  or	  B-­‐PEG	  and	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binding	  directly	  to	  the	  gold	  surface	  of	  the	  nanoparticle.	  This	  binding	  event	  would	  mean	  the	  number	  of	  polyGL	  per	  particle	  would	  not	  need	  to	  correspond	  directly	  to	  the	  amount	  of	  avidin	  per	  particle.	  Furthermore,	  the	  concentration	  of	  AuNPs	  in	  solution	  was	  set	  using	  the	  absorbance	  of	  the	  sample	  at	  524	  nm,	  the	  wavelength	  at	  which	  avidin	  AuNPs	  maximally	  absorb.	  However,	  the	  addition	  of	  polyGL	  often	  results	  in	  a	  wider	  peak	  than	  avidin	  AuNPs,	  so	  matching	  the	  concentration	  of	  gold	  nanoparticles	  only	  to	  the	  maximum	  absorption	  at	  524	  nm	  likely	  underestimates	  the	  true	  concentration	  of	  AuNPs	  in	  solution	  in	  polyGL	  samples.	  To	  truly	  standardize	  these	  concentrations,	  it	  may	  be	  valuable	  to	  use	  ICP-­‐OES	  to	  measure	  the	  concentration	  of	  gold	  in	  solution	  in	  the	  future,	  rather	  than	  UV-­‐vis.	  Whatever	  the	  case,	  the	  CBQCA	  assay	  was	  very	  clear	  that	  polyGL	  AuNPs	  had	  a	  significantly	  higher	  amount	  of	  amines	  in	  solution	  than	  avidin	  AuNPs,	  a	  strong	  indication	  that	  polyGL	  had,	  in	  fact,	  bound	  to	  avidin.	  	  
Future	  Considerations	  With	  the	  success	  of	  gel	  electrophoresis	  and	  the	  CBQCA	  assay,	  it	  appears	  that	  all	  the	  pieces	  are	  in	  place	  for	  a	  complete	  nanovehicle	  for	  the	  treatment	  of	  pancreatic	  cancer.	  To	  improve	  the	  reliability	  of	  the	  CBQCA	  assay,	  it	  would	  be	  useful	  to	  run	  this	  same	  assay	  on	  one	  batch	  of	  AuNPs	  at	  each	  stage	  of	  functionalization,	  as	  the	  current	  calculations	  were	  done	  on	  two	  separate	  samples,	  which	  have	  had	  different	  levels	  of	  success	  with	  avidin	  binding.	  Reproducing	  this	  data	  with	  a	  sample	  before	  and	  after	  the	  addition	  of	  polyGL	  would	  go	  far	  to	  reduce	  some	  potential	  for	  error	  when	  estimating	  the	  effect	  of	  avidin	  on	  the	  fluorescence	  signal	  in	  polyGL	  samples.	  However,	  if	  the	  numbers	  remain	  consistent,	  the	  next	  logical	  step	  would	  be	  to	  attempt	  to	  bind	  both	  polyGL	  and	  As33	  to	  avidin	  AuNPs,	  to	  make	  sure	  that	  these	  two	  species	  can	  bind	  without	  undue	  competition	  and	  remain	  functional.	  Functionality	  of	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As33	  could	  be	  measured	  through	  cell	  uptake	  trials,	  wherein	  the	  fully	  functionalized	  AuNPs	  could	  be	  introduced	  to	  cancerous	  pancreatic	  cell	  lines.	  If	  uptake	  occurred,	  it	  could	  be	  seen	  either	  through	  DIC	  imaging44	  or	  measured	  through	  the	  use	  of	  inductive-­‐coupled	  plasma	  techniques,	  such	  as	  ICP-­‐OES.45	  The	  ratio	  of	  antibodies	  per	  particle	  may	  need	  to	  be	  adjusted	  based	  on	  the	  results	  of	  cell	  binding	  and	  uptake	  studies,	  and	  the	  concentration	  of	  avidin	  per	  particle	  should	  most	  likely	  be	  increased,	  to	  accommodate	  both	  As33	  and	  polyGL	  on	  the	  surface.	  However,	  these	  adjustments	  would	  most	  likely	  be	  straightforward,	  as	  it	  is	  clear	  from	  the	  results	  stated	  here	  that	  each	  piece	  of	  this	  nanovehicle	  is	  independently	  bound	  and	  functional.	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Conclusions	  	   Our	  goal	  in	  the	  present	  work	  was	  to	  build	  upon	  previous	  results	  to	  continue	  creating	  a	  nanovehicle	  to	  target	  and	  treat	  pancreatic	  cancer.	  Through	  the	  use	  of	  a	  biotin-­‐avidin	  conjugation	  system,	  we	  successfully	  functionalized	  11.2	  nm	  gold	  nanoparticles	  with	  targeting	  antibody	  As33	  and	  polyGL.	  These	  particles	  possess	  a	  stabilizing	  C-­‐PEG	  and	  B-­‐PEG	  “stealth”	  coat	  for	  biocompatibility	  as	  well	  as	  avidin	  handles	  as	  sites	  for	  As33	  and	  the	  treatment	  platform	  polyGL	  binding.	  Overall,	  we	  demonstrated:	  (1) Avidin	  molecules	  can	  be	  bound	  to	  PEGylated	  nanoparticles	  through	  interactions	  with	  biotin-­‐PEG-­‐thiol.	  These	  avidin	  molecules	  remain	  capable	  of	  further	  biotin	  binding	  through	  remaining	  open	  binding	  sites.	  	  (2) As33	  can	  be	  successfully	  covalently	  modified	  with	  biotinylated	  or	  thiolated	  PEG	  linkers	  for	  conjugation	  to	  nanovehicles,	  either	  through	  biotin-­‐avidin	  conjugation	  or	  direct	  interaction	  with	  the	  gold	  surface.	  	  (3) As33	  can	  be	  bound	  to	  particles	  through	  biotin-­‐avidin	  interactions	  or	  direct	  covalent	  linkage	  to	  gold	  surfaces.	  The	  number	  of	  antibodies	  per	  particle	  can	  be	  quantified	  with	  ELISAs.	  (4) PolyGL	  can	  be	  successfully	  biotinylated	  by	  reacting	  lysines	  with	  sulf-­‐NHS-­‐biotin.	  This	  biotinylation	  can	  be	  observed	  through	  dot-­‐blots	  and	  quantified	  using	  the	  Quant*Tag	  Biotin	  Quantification	  Kit	  by	  Chromalink.	  	  (5) Biotinylated	  polyGL	  can	  be	  conjugated	  to	  gold	  nanoparticles	  through	  biotin-­‐avidin	  interactions	  with	  avidin	  AuNPs.	  The	  addition	  of	  polyGL	  to	  the	  nanovehicle	  is	  measureable	  through	  gel	  electrophoresis	  and	  the	  CBQCA	  Protein	  Quantification	  Assay.	  
	   55	  
	  Each	  step	  in	  the	  surface	  functionalization	  of	  a	  gold	  nanovehicle	  to	  target	  and	  treat	  pancreatic	  cancer	  has	  successfully	  been	  performed	  and	  validated.	  These	  individual	  steps	  will	  need	  to	  be	  combined	  to	  form	  a	  complete	  nanovehicle,	  which	  may	  then	  be	  tested	  within	  cell	  lines.	  In	  addition,	  boron	  needs	  to	  be	  conjugated	  to	  polyGL	  before	  treatment	  could	  be	  administered.	  However,	  each	  step	  within	  the	  process	  of	  nanovehicle	  construction	  has	  been	  successful,	  which	  brings	  nanoscience	  a	  few	  steps	  closer	  to	  a	  safer	  and	  more	  effective	  treatment	  for	  pancreatic	  cancer.	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Figure	  A-­‐	  1:	  Biotin	  dot-­‐blot	  of	  As33	  modified	  with	  the	  Chromalink	  kit.	  	  Serial	  dilution,	  from	  20	  μg	  to	  1.25	  μg	  of	  protein,	  of	  biotin	  modified	  monoclonal	  antibody	  As33	  in	  the	  presence	  of	  HRP-­‐conjugated	  anti-­‐biotin	  antibody	  indicated	  the	  presence	  of	  biotin,	  further	  supported	  by	  the	  absence	  of	  signal	  from	  negative	  control	  PBS.	  It	  is	  thought	  that	  the	  positive	  control,	  unbound	  biotin	  molecules,	  may	  have	  been	  too	  concentrated	  to	  react	  with	  anti-­‐biotin	  antibodies.	  	  
	  
Figure	  A-­‐	  2:	  Anti-­‐biotin	  dot	  blot	  of	  polyGL.	  Samples	  were	  spotted	  onto	  nitrocellulose	  membranes	  and	  incubated	  in	  anti-­‐biotin	  HRP	  conjugated	  antibodies.	  The	  leftmost	  spot	  represents	  a	  biotin	  standard,	  as	  a	  positive	  control;	  left	  of	  that	  spot,	  in	  the	  “empty	  space”	  is	  the	  negative	  control,	  PBS.	  The	  right	  three	  spots	  are	  three	  separate	  samples	  of	  biotinylated	  polyGL,	  where	  one	  conjugation	  was	  lower	  than	  the	  others.	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Figure	  A-­‐	  3:	  Anti-­‐biotin	  dot	  blot	  of	  As33	  modified	  through	  the	  Kumar	  method.	  	  Samples	  were	  spotted	  onto	  nitrocellulose	  membranes	  and	  incubated	  in	  anti-­‐biotin	  HRP	  conjugated	  antibodies.	  The	  spot	  furthest	  to	  the	  left	  corresponds	  to	  the	  biotin	  standard,	  acting	  as	  a	  positive	  control,	  whereas	  the	  spot	  on	  the	  outer	  right	  is	  modified	  As33.	  Not	  shown	  are	  negative	  controls	  PBS,	  C-­‐PEG	  AuNPS,	  avidin	  AuNPs,	  and	  unmodified	  As33.	  	  
	  
Figure	  A-­‐	  4:	  As33	  standard	  curve	  for	  the	  calibration	  of	  ELISAs.	  Samples	  from	  0	  ng/mL	  to	  125	  ng/mL	  were	  prepared	  as	  a	  standard	  curve	  against	  which	  to	  measure	  the	  absorbance	  at	  450	  nm	  of	  experimental	  samples.	  
	  	  
A 	  B	   	  
Figure	  A-­‐	  5:	  Zeta-­‐Potential	  shows	  minimal	  and	  insignificant	  shifts	  in	  charge	  as	  particles	  are	  
functionalized.	  In	  (A)	  the	  Zeta	  Potential	  distribution	  of	  dilute	  avidin	  AuNPs	  is	  shown,	  as	  prepared	  by	  Malvern	  software.	  In	  comparison,	  (B)	  shows	  the	  Zeta	  Potential	  distribution	  for	  dilute	  polyGL	  AuNPs.	  Dilution	  factors	  were	  held	  constant	  between	  the	  two	  samples.	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Figure	  A-­‐	  6:	  Quant*Tag	  biotin	  standard	  curve.	  Following	  manufacturer’s	  instructions,	  a	  standard	  curve	  of	  biotin	  was	  prepared	  for	  this	  colorimetric	  assay.	  All	  data	  was	  set	  to	  this	  curve	  for	  this	  analysis.	  
	  
	  
Figure	  A-­‐	  7:	  Avidin	  standard	  curve	  for	  CBQCA	  assay.	  In	  the	  analysis	  of	  CBQCA	  protein	  quantification	  assays,	  six	  solutions	  from	  0-­‐1000	  ng	  of	  avidin	  were	  produced,	  each	  with	  10	  μl	  of	  M-­‐PEG	  AuNPs	  at	  1	  OD	  added	  to	  compensate	  for	  the	  effect	  of	  gold	  on	  fluorescence	  emission.	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Figure	  A-­‐	  8:	  PolyGL	  standard	  curve	  for	  CBQCA	  assay.	  In	  the	  analysis	  of	  CBQCA	  protein	  quantification	  assays,	  six	  solutions	  from	  0-­‐1000	  ng	  of	  polyGL	  were	  produced,	  each	  with	  10	  μl	  of	  M-­‐PEG	  AuNPs	  at	  1	  OD	  added	  to	  compensate	  for	  the	  effect	  of	  gold	  on	  fluorescence	  emission.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
